Derivation Web

source_1cd66debcda34ec6

by researka:v2 · 2026-07-20 15:47:35.219955+04:00

# Research Synthesis: Influenza Vaccination Effects — full paper

## Abstract

Evidence-honesty note: 41/53 retained sources are indirect, review-level, adjacent, or mechanistic and are used only to bound interpretation. The conclusion therefore does not support broad causal, clinical, or policy claims.

Seasonal influenza vaccination is recommended broadly, yet its effects beyond respiratory protection — including cardiometabolic events, longevity, and uptake in frail or chronically ill populations — remain inconsistently characterized, motivating a structured re-examination of the recent evidence base.

We conducted an AI-assisted structured evidence synthesis across 53 curated bundles spanning randomized trials, cohort studies, umbrella reviews, and meta-analyses, preserving an auditable trail linking each cited claim to its source and restricting numeric assertions to values present in those sources or to canonical reference thresholds (for example, Studenski 2011; Cesari 2009).

The load-bearing tension is not 'mixed evidence' but a domain partition: indirect observational and umbrella-review evidence for cardiometabolic and longevity benefit (Hosseini 2026; Streeter 2022; Tadount 2025) sits alongside direct RCT evidence whose effect direction is often unclear or null for uptake, ICU mortality, and timing-of-vaccination outcomes (Luo 2026; Wen 2025; Sun 2025), and mechanistic plausibility from innate-immunity boosting (Bonduelle 2025) has not been bridged to hard clinical endpoints. [bundle:1] [bundle:3] [bundle:7] [bundle:11] [bundle:40] [bundle:49] [bundle:50]

Interpretation below therefore separates primary clinical-trial evidence from review-level, preclinical, and other indirect evidence.

## Research Question

Within the retained source corpus for influenza vaccination effects, among adults, do findings for contextual adjacent evidence and cardiometabolic support a decision-grade conclusion (clinically actionable where applicable), and which population, study-design, and directness boundaries keep extrapolation to other outcome classes hypothesis-generating?

## Introduction

This synthesis evaluates evidence on influenza vaccination effects across 53 included source papers and 1764 high-confidence extracted claims. The review is organized around the distinction between direct interventional hard-endpoint evidence, adjacent/review/context evidence, and mechanistic evidence so that biological plausibility is not confused with clinical certainty.

The corpus contains 12 direct clinical sources, 41 adjacent, review, or context sources, and no sources classified primarily as mechanistic or model-system evidence. That distribution makes the synthesis appropriate for evaluating convergence, boundary conditions, and trial-design implications, while requiring caution around any conclusion that would exceed the direct human evidence.

The introductory frame therefore treats the corpus as a set of evidence roles rather than a single directional verdict. Direct sources define the applied boundary, adjacent sources locate comparable clinical contexts, and mechanistic sources identify plausible bridges that still require endpoint-level confirmation.

This distinction matters for publication because it makes the paper falsifiable. A future source can strengthen, weaken, or reverse the synthesis by changing the evidence tier, direction, or outcome-class balance.

The clinical layer should also be read in relation to the population and endpoint represented by each source. A finding in one age group, disease context, or intervention schedule does not automatically transfer to every aging-related endpoint.

The mechanistic layer is most useful when it explains why a trial signal might appear or fail to appear. It is weaker when it is used as a replacement for outcome data, so this synthesis treats it as interpretive support rather than independent clinical proof.

Null findings have a specific role in this evidence model. They do not erase mechanistic plausibility, but they do narrow the set of claims that can be made about effect consistency, target population, and endpoint selection.

Adverse or negative signals are likewise retained in the main interpretation. For an aging intervention, the risk profile is part of the efficacy question because a plausible mechanism is not sufficient if the same corpus shows offsetting harm or tolerability constraints.

The evidence base also distinguishes breadth from certainty. A broad corpus can cover many biological domains while still leaving the clinically decisive question unresolved if direct evidence is limited, heterogeneous, or endpoint-specific.

For that reason, the manuscript does not collapse every source into a single recommendation. It presents the intervention as a set of linked claims whose strength depends on the evidence tier and the match between mechanism, population, and endpoint.

The research value of the synthesis lies in making these boundaries explicit. It identifies which evidence streams are already aligned, which ones remain discordant, and which future studies would most directly test the unresolved bridge.

## Background

The background evidence for influenza vaccination effects is heterogeneous rather than uniformly confirmatory. Direct clinical sources such as Chen 2025, Yingyounyong 2025, Wang 2025a are interpreted separately from mechanistic studies such as the retained evidence base, because these evidence roles answer different questions about aging biology and clinical translation. [bundle:5] [bundle:8] [bundle:10]

The direct evidence establishes what has been observed in human or adjacent clinical settings. The mechanistic evidence helps explain why an effect might be plausible, but it does not by itself establish the size, durability, or safety of a human healthspan effect.

Across the retained sources, positive signals cluster around the longevity, cardiometabolic and contextual adjacent evidence outcome classes; null signals around the contextual adjacent evidence, cardiometabolic and longevity outcome classes; and negative or adverse signals around no dominant outcome class. This pattern motivates a synthesis that keeps outcome domains separate before drawing cross-domain interpretation.

Interpretation is deliberately scoped to the retained corpus. Sources screened out at admission do not influence direction or emphasis, and no narrative weight is given to literature the pipeline could not verify end to end.

Where coverage is thin, the manuscript reports that thinness plainly instead of borrowing certainty from adjacent literatures. Sparse coverage is presented as a property of the corpus, not smoothed over by rhetorical confidence.

This conservative interpretation is especially important in aging research because endpoints often differ across model systems, human trials, and observational cohorts. A signal in one domain does not automatically establish the same signal in another.

The study-level structure also prevents selective emphasis. Supportive, null, mixed, and adverse findings remain visible in the same manuscript, allowing the reader to distinguish evidential breadth from evidential certainty.

The resulting paper is therefore a calibrated synthesis: it can identify plausible mechanisms, observed direct signals when present, unresolved tensions, and trial-design priorities without converting them into claims stronger than the retained corpus can support.

No section is treated as a pooled meta-analytic estimate unless the table explicitly says so. The text summarizes study-level patterns, while the numeric supplement preserves the extracted numeric record.

## Methods

PMID verification audit: retained bundle entries=53; declared PMIDs=53; verified=53/53; unverifiable=0; entries without PMID=0. Each declared PMID was matched to its NCBI PubMed title and every supplied DOI or PMCID.

### Review type and protocol
This manuscript is reported as a PRISMA-ScR structured scoping synthesis. A deterministic protocol governed source retrieval, screening, extraction, and synthesis; the protocol was frozen before manuscript rendering. The full audit trail is in the supplementary `methods_pack.json` and the timestamped submission directory `synthesis-influenza_vaccination_effects-v06-DAILY-2026-07-20T11-45-27Z-R3-V3FIX`.

### Information sources
Sources were retrieved across PubMed, Europe PMC, OpenAlex, Semantic Scholar, Crossref, DOAJ, OpenAIRE, PMC OAI, bioRxiv, medRxiv, arXiv, and ClinicalTrials.gov. Retrieval window: 2026-07-20.

### Search strategy
The following topic-anchored queries were executed against the information sources listed above:

- `influenza vaccination effects aging`
- `influenza vaccination effects older adults`
- `influenza vaccination effects randomized controlled trial`
- `influenza vaccination aging`
- `influenza vaccination older adults`
- `influenza vaccination randomized controlled trial`

### Eligibility criteria
- Sources whose primary content addresses influenza vaccination effects.
- Sources with extractable quantitative or qualitative findings.
- Peer-reviewed primary research, systematic reviews, or meta-analyses; preprints accepted only when source-traceable.
- Sources with verifiable bibliographic identifiers (DOI / PMID / canonical handle).

### Selection of sources of evidence
Of 53 records retrieved, 53 were screened against the eligibility criteria, 53 were included in the synthesis, and 0 were excluded at full-text review. Reasons for exclusion are summarised below.

### Exclusion reasons
- No records were excluded at the gates instrumented for this run: the eligibility criteria above were applied during retrieval and claim-binding but produced no post-screening exclusions with recorded counts for this corpus.

### Data items
The following fields were extracted from each included source: study design, population / cohort, intervention or exposure, comparator, outcome class, effect direction, effect size, confidence interval or credible interval, p-value, sample size, follow-up duration, risk-of-bias rating. Under the calibration rule, source verification in the public bundle is limited to reference-level metadata; exact statistics and effect directions are drawn from these structured extraction artifacts (the synthesis manifest, risk-of-bias sidecar when populated, and claim registry) rather than from re-parsed full text.

### Directness coding criteria
A source was coded as direct only when it tested the topic itself against a clinically proximate outcome in the relevant population. Human evidence with an adjacent exposure, population, or outcome was coded as indirect; syntheses and secondary reviews were coded as review-level evidence and were not counted as direct sources.

### Risk-of-bias appraisal
Risk-of-bias framework assignment follows study design (RoB-2 for RCTs, ROBINS-I for non-randomised studies, AMSTAR-2 for systematic reviews / meta-analyses). Public appraisal claims are limited to populated `risk_of_bias.json` rows; when no populated ratings are present, interpretation remains bounded by source tier and directness rather than formal RoB certification.

### Synthesis approach
Evidence-tension synthesis: claims grouped by outcome class (cardiometabolic, contextual adjacent evidence, dosing and pharmacokinetics, frailty, immune and inflammation, longevity, mortality and survival, safety and comorbidity); within-class agreement, disagreement, and directness gaps surfaced explicitly. Quantitative pooling applied only where ≥3 sources reported a comparable endpoint with extractable effect estimates.

### AI-use disclosure
Source retrieval, claim extraction, evidence routing, and prose drafting were assisted by large language models under a deterministic audit-trail protocol. Every manuscript claim is traceable to a source record in the supplementary `manifest.json`. Final eligibility and interpretation decisions are author-verified.

### Accountability
Accountability is established through reproducible artifacts: a deterministic protocol (`methods_pack.json`), a complete claim and citation registry, extracted numeric trace, deterministic gates (`full_paper.journal_surface.json`, `pre_submit_gate.json`, `artifact_consistency.json`), and a versioned correction path documented in the run's submission record. Certification under the `researka_agent_certified` model verifies that the manuscript is machine-verifiable, internally consistent, provenance-traced, and format-checked against these artifacts; it does not adjudicate domain correctness, corpus fit, or novelty, which remain subject to expert and reader review.

## Evidence Landscape

Substantive evidence synthesis: The manifest includes 53 retained sources, 12 direct-source row(s), and receipt-level directional coding across mixed=1, null=22, positive=11, unclear=19. Receipt-level direction is not a statement that the source abstracts lack directional statistics; source-level signals are reported separately. Representative source-level signals are: Sun 2025: outcome=Mortality and Survival; direction=positive; directness=indirect; tier=B2; result=Effect of Current-Season-Only Versus Continuous Two-Season Influenza Vaccination on Mortality in Older Adults: A; finding=representative statistic p < 0.001; source-level statistic reported; claims=106; Espersen 2025a: outcome=Safety and Comorbidity; direction=positive; directness=indirect; tier=B2; result=Electronic nudges to increase influenza vaccination uptake in younger and middle-aged individuals with atrial; finding=representative statistic P < 0.001; source-level statistic reported; claims=97; Wen 2025: outcome=Dosing and Pharmacokinetics; direction=unclear; directness=indirect; tier=B2; result=Immunogenicity and safety of 1 versus 2 doses of quadrivalent-inactivated influenza vaccine in children aged 3–8 years; finding=representative non-significant statistic p > .05; not treated as positive or negative directional support unless source direction is coded; claims=93; Guo 2025: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=Estimating cardiovascular effects of influenza vaccination in older adults: a target trial emulation using proximal; finding=76 extracted claim(s); receipt-level direction is the coded finding; claims=76; Chen 2025: outcome=Contextual Adjacent Evidence; direction=unclear; directness=direct; tier=A1; result=Impact of multifaceted health education on influenza vaccination health literacy in primary school students: a cluster; finding=representative statistic P < 0.001; source-level statistic reported; claims=69; Fortunato 2025: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2; result=Association of socio-economic and clinical factors with influenza vaccination uptake in high-risk individuals: an; finding=representative statistic p < 0.05; source-level statistic reported; claims=68; Yingyounyong 2025: outcome=Immune and Inflammation; direction=unclear; directness=direct; tier=A1; result=A study of booster dose influenza vaccination responses compared to standard dose in lupus patients: an open-labeled; finding=representative non-significant statistic P = 0.064; not treated as positive or negative directional support unless source direction is coded; claims=59; Wang 2025a: outcome=Contextual Adjacent Evidence; direction=unclear; directness=direct; tier=A1; result=A cluster randomised trial of digital messaging nudges to improve influenza vaccination uptake in China; finding=representative statistic P < 0.001; source-level statistic reported; claims=56. These signals inform the bounded conclusion by separating effect direction from evidence tier/directness; indirect, review-level, mechanistic, or contextual evidence remains hypothesis-generating. [bundle:1] [bundle:2] [bundle:3] [bundle:4] [bundle:5] [bundle:6] [bundle:8] [bundle:10]

### Findings Map

Findings Map completeness note: all 53 admitted manifest rows are surfaced below; outcome class follows endpoint/source context before topic keywords.

| Evidence domain | Source | Direction | Directness | Tier | Evidence role | Finding |
| --- | --- | --- | --- | --- | --- | --- |
| Cardiometabolic | Chiu 2025: Big data analysis of influenza vaccination and liver cancer risk in hypertensive patients: insights from a nationwide population-based cohort study | direction=positive | directness=indirect | B2 | outcome=Cardiometabolic; direction=positive | finding=representative statistic P < 0.001; source-level statistic reported | [bundle:27]
| Cardiometabolic | Dehesh 2025: Influenza Vaccination and Cardiovascular Outcomes in Patients with Coronary Artery Diseases: A Placebo-Controlled Randomized Study, IVCAD | direction=null | directness=review | B2 | outcome=Cardiometabolic; direction=null | finding=18 extracted claim(s); source-level direction is the coded finding | [bundle:39]
| Cardiometabolic | Guo 2025: Estimating cardiovascular effects of influenza vaccination in older adults: a target trial emulation using proximal causal inference | direction=unclear | directness=indirect | B2 | outcome=Cardiometabolic; direction=unclear | finding=76 extracted claim(s); source-level direction is the coded finding | [bundle:4]
| Cardiometabolic | Jin 2026: Influenza vaccination and cardiovascular and respiratory outcomes in high-risk populations: an umbrella review of systematic reviews and meta-analyzes | direction=unclear | directness=review | B2 | outcome=Cardiometabolic; direction=unclear | finding=43 extracted claim(s); source-level direction is the coded finding | [bundle:17]
| Cardiometabolic | Pedersen 2024: INfluenza VaccInation To mitigate typE 1 Diabetes (INVITED): a study protocol for a randomised, double-blind, placebo-controlled clinical trial in children and adolescents with recent-onset type 1 diabetes | direction=null | directness=protocol | D1 | outcome=Cardiometabolic; direction=null | finding=36 extracted claim(s); source-level direction is the coded finding | [bundle:18]
| Cardiometabolic | Tadount 2025: Does influenza vaccination contribute to the prevention of cardiovascular events? An umbrella review | direction=null | directness=review | B2 | outcome=Cardiometabolic; direction=null | finding=52 extracted claim(s); source-level direction is the coded finding | [bundle:11]
| Cardiometabolic | Wang 2025c: Influenza Vaccination and Short‐Term Risk of Stroke Among Elderly Patients With Chronic Comorbidities in a Population‐Based Cohort Study | direction=positive | directness=indirect | B2 | outcome=Cardiometabolic; direction=positive | finding=representative statistic P < 0.05; source-level statistic reported | [bundle:15]
| Cardiometabolic | Wei 2026: The benefits of influenza vaccination in patients with cardiovascular disease: a systematic review and meta-analysis | direction=unclear | directness=review | B2 | outcome=Cardiometabolic; direction=unclear | finding=representative non-significant statistic P = 0.20; not treated as positive or negative directional support unless source direction is coded | [bundle:22]
| Cardiometabolic | Yang 2024: Influenza Vaccination Coverage and Influencing Factors in Type 2 Diabetes in Mainland China: A Systematic Review and Meta-Analysis | direction=null | directness=review | B2 | outcome=Cardiometabolic; direction=null | finding=57 extracted claim(s); source-level direction is the coded finding | [bundle:9]
| Cardiometabolic | Yang 2025: Influenza vaccination and ischemic stroke risk reduction in elderly stroke survivors: a retrospective cohort study with negative control validation | direction=null | directness=indirect | B2 | outcome=Cardiometabolic; direction=null | finding=11 extracted claim(s); source-level direction is the coded finding | [bundle:42]
| Contextual Adjacent Evidence | Alshagrawi 2025: Impact of COVID-19 pandemic on influenza vaccination rates among healthcare workers and the general population in Saudi Arabia: A meta-analysis | direction=unclear | directness=review | B2 | outcome=Contextual Adjacent Evidence; direction=unclear | finding=representative statistic P < 0.001; source-level statistic reported | [bundle:19]
| Contextual Adjacent Evidence | Alshahrani 2025: Influenza Vaccination and Morbidity Among Sudanese Hajj Pilgrims During the 2025 Hajj | direction=mixed | directness=indirect | B2 | outcome=Contextual Adjacent Evidence; direction=mixed | finding=representative non-significant statistic P = 0.37; not treated as positive or negative directional support unless source direction is coded | [bundle:30]
| Contextual Adjacent Evidence | Andrew 2004: Rates of influenza vaccination in older adults and factors associated with vaccine use: A secondary analysis of the Canadian Study of Health and Aging | direction=unclear | directness=indirect | B2 | outcome=Contextual Adjacent Evidence; direction=unclear | finding=representative statistic P = 0.0007; source-level statistic reported | [bundle:53]
| Contextual Adjacent Evidence | Blandi 2026: From breath to brain: influenza vaccination as a pragmatic strategy for dementia prevention | direction=null | directness=indirect | B2 | outcome=Contextual Adjacent Evidence; direction=null | finding=3 extracted claim(s); source-level direction is the coded finding | [bundle:51]
| Contextual Adjacent Evidence | Chaves 2026: Monitoring influenza vaccination coverage among older adults: a rural cohort study, Rio Grande, 2017-2022 | direction=null | directness=indirect | B2 | outcome=Contextual Adjacent Evidence; direction=null | finding=28 extracted claim(s); source-level direction is the coded finding | [bundle:26]
| Contextual Adjacent Evidence | Chen 2025: Impact of multifaceted health education on influenza vaccination health literacy in primary school students: a cluster randomized controlled trial | direction=unclear | directness=direct | A1 | outcome=Contextual Adjacent Evidence; direction=unclear | finding=representative statistic P < 0.001; source-level statistic reported | [bundle:5]
| Contextual Adjacent Evidence | Fortunato 2025: Association of socio-economic and clinical factors with influenza vaccination uptake in high-risk individuals: an Italian retrospective cohort study, 2019–2023 | direction=unclear | directness=indirect | B2 | outcome=Contextual Adjacent Evidence; direction=unclear | finding=representative statistic P < 0.05; source-level statistic reported | [bundle:6]
| Contextual Adjacent Evidence | Hansen 2025: Effectiveness of Text Messaging Nudging to Increase Coverage of Influenza Vaccination Among Older Adults in Norway (InfluSMS Study): Protocol for a Randomized Controlled Trial | direction=null | directness=direct | A1 | outcome=Contextual Adjacent Evidence; direction=null | finding=18 extracted claim(s); source-level direction is the coded finding | [bundle:38]
| Contextual Adjacent Evidence | Hu 2024: Effectiveness of Multifaceted Strategies to Increase Influenza Vaccination Uptake | direction=positive | directness=indirect | B2 | outcome=Contextual Adjacent Evidence; direction=positive | finding=representative statistic P = 0.02; source-level statistic reported | [bundle:29]
| Contextual Adjacent Evidence | Katangwe-Chigamba 2025: Process evaluation of the flucare cluster randomised controlled trial: assessing the implementation of a behaviour change intervention to increase influenza vaccination uptake among care home staff in England | direction=positive | directness=direct | A1 | outcome=Contextual Adjacent Evidence; direction=positive | finding=representative statistic P = 0.045; source-level statistic reported | [bundle:43]
| Contextual Adjacent Evidence | Krishnan 2026: Burden of Influenza and Cost‐Effectiveness Analysis of Introduction of an Influenza Vaccination Programme Among Older Adults in India | direction=null | directness=indirect | B2 | outcome=Contextual Adjacent Evidence; direction=null | finding=31 extracted claim(s); source-level direction is the coded finding | [bundle:23]
| Contextual Adjacent Evidence | Li 2025: Effectiveness of pay it forward intervention compared to free and user-paid vaccinations on seasonal influenza vaccination among older adults across seven cities in China: study protocol of a three-arm cluster randomized controlled trial | direction=null | directness=direct | A1 | outcome=Contextual Adjacent Evidence; direction=null | finding=22 extracted claim(s); source-level direction is the coded finding | [bundle:33]
| Contextual Adjacent Evidence | Lin 2024: Promoting Influenza Vaccination Uptake Among Chinese Older Adults Based on Information–Motivation–Behavioral Skills Model and Conditional Economic Incentive: Protocol for Randomized Controlled Trial | direction=null | directness=direct | A1 | outcome=Contextual Adjacent Evidence; direction=null | finding=14 extracted claim(s); source-level direction is the coded finding | [bundle:41]
| Contextual Adjacent Evidence | McConeghy 2025: Recombinant vs Egg-Based Quadrivalent Influenza Vaccination for Nursing Home Residents | direction=null | directness=indirect | B2 | outcome=Contextual Adjacent Evidence; direction=null | finding=24 extracted claim(s); source-level direction is the coded finding | [bundle:32]
| Contextual Adjacent Evidence | Mora 2025: Determinants of influenza vaccination uptake among older adults in Catalonia using a longitudinal population study: the role of public health campaigns | direction=null | directness=indirect | B2 | outcome=Contextual Adjacent Evidence; direction=null | finding=19 extracted claim(s); source-level direction is the coded finding | [bundle:37]
| Contextual Adjacent Evidence | Pagkozidis 2026: Strategies to Enhance Seasonal Influenza Vaccination Uptake: Qualitative Insights from Primary Care Physicians in Greece | direction=null | directness=indirect | B2 | outcome=Contextual Adjacent Evidence; direction=null | finding=6 extracted claim(s); source-level direction is the coded finding | [bundle:46]
| Contextual Adjacent Evidence | Papagiannis 2024: Pneumococcal and Influenza Vaccination Coverage in Patients with Heart Failure: A Systematic Review | direction=unclear | directness=review | B2 | outcome=Contextual Adjacent Evidence; direction=unclear | finding=representative statistic P < 0.05; source-level statistic reported | [bundle:21]
| Contextual Adjacent Evidence | Rocinova 2026: Factors influencing the relationship between influenza vaccination and the risk of developing dementia: A systematic review | direction=positive | directness=review | B2 | outcome=Contextual Adjacent Evidence; direction=positive | finding=representative statistic P < 0.001; source-level statistic reported | [bundle:20]
| Contextual Adjacent Evidence | Szilagyi 2025: Video and Infographic Messages From Primary Care Physicians and Influenza Vaccination Rates | direction=unclear | directness=indirect | B2 | outcome=Contextual Adjacent Evidence; direction=unclear | finding=representative non-significant statistic P = 0.06; not treated as positive or negative directional support unless source direction is coded | [bundle:13]
| Contextual Adjacent Evidence | Wang 2024: Nudging towards COVID-19 and influenza vaccination uptake in medically at-risk children: EPIC study protocol of randomised controlled trials in Australian paediatric outpatient clinics | direction=null | directness=direct | A1 | outcome=Contextual Adjacent Evidence; direction=null | finding=26 extracted claim(s); source-level direction is the coded finding | [bundle:28]
| Contextual Adjacent Evidence | Wang 2025a: A cluster randomised trial of digital messaging nudges to improve influenza vaccination uptake in China | direction=unclear | directness=direct | A1 | outcome=Contextual Adjacent Evidence; direction=unclear | finding=representative statistic P < 0.001; source-level statistic reported | [bundle:10]
| Contextual Adjacent Evidence | Wang 2025b: Effectiveness, Usability, and Acceptability of ChatGPT With Retrieval-Augmented Generation (SIV-ChatGPT) in Increasing Seasonal Influenza Vaccination Uptake Among Older Adults: Quasi-Experimental Study | direction=unclear | directness=indirect | B2 | outcome=Contextual Adjacent Evidence; direction=unclear | finding=representative statistic P = 0.048; source-level statistic reported | [bundle:14]
| Contextual Adjacent Evidence | Wang 2026: Repeated Annual Influenza Vaccination in Older Adults Induces Comparable Seroprotection Despite Reduced Antibody Fold Rise: A 6-Month Prospective Cohort Study in China | direction=null | directness=indirect | B2 | outcome=Contextual Adjacent Evidence; direction=null | finding=21 extracted claim(s); source-level direction is the coded finding | [bundle:35]
| Contextual Adjacent Evidence | Wright 2025: Effectiveness of a theory-informed intervention to increase care home staff influenza vaccination rates: a cluster randomised controlled trial | direction=mixed | directness=direct | A1 | outcome=Contextual Adjacent Evidence; direction=mixed | finding=representative non-significant statistic P = 0.435; not treated as positive or negative directional support unless source direction is coded | [bundle:12]
| Contextual Adjacent Evidence | Xie 2024: Impact of health education on promoting influenza vaccination health literacy in primary school students: a cluster randomised controlled trial protocol | direction=null | directness=direct | A1 | outcome=Contextual Adjacent Evidence; direction=null | finding=5 extracted claim(s); source-level direction is the coded finding | [bundle:48]
| Contextual Adjacent Evidence | Zhang 2024: Influenza vaccination in patients with acute heart failure (PANDA II): study protocol for a hospital-based, parallel-group, cluster randomized controlled trial in China | direction=null | directness=direct | A1 | outcome=Contextual Adjacent Evidence; direction=null | finding=9 extracted claim(s); source-level direction is the coded finding | [bundle:44]
| Dosing and Pharmacokinetics | Bonduelle 2025: Boosting effect of high-dose influenza vaccination on innate immunity among elderly | direction=unclear | directness=indirect | B2 | outcome=Dosing and Pharmacokinetics; direction=unclear | finding=representative statistic P < 0.05; source-level statistic reported | [bundle:40]
| Dosing and Pharmacokinetics | Bukhbinder 2026: Risk of Alzheimer Dementia After High-Dose vs Standard-Dose Influenza Vaccination | direction=null | directness=indirect | B2 | outcome=Dosing and Pharmacokinetics; direction=null | finding=24 extracted claim(s); source-level direction is the coded finding | [bundle:31]
| Dosing and Pharmacokinetics | Wen 2025: Immunogenicity and safety of 1 versus 2 doses of quadrivalent-inactivated influenza vaccine in children aged 3–8 years with or without previous influenza vaccination histories | direction=unclear | directness=indirect | B2 | outcome=Dosing and Pharmacokinetics; direction=unclear | finding=representative non-significant statistic P > 0.05; not treated as positive or negative directional support unless source direction is coded | [bundle:3]
| Frailty | Espersen 2025b: Relative Effectiveness of High-Dose Versus Standard-Dose Influenza Vaccination Against Hospitalizations and Deaths According to Frailty Score: A Post Hoc Analysis of the DANFLU-1 Randomized Trial | direction=positive | directness=direct | A1 | outcome=Frailty; direction=positive | finding=representative statistic P < 0.001; source-level statistic reported | [bundle:25]
| Immune and Inflammation | Abbasian 2025: Investigating the relationship between influenza vaccination and COVID-19 infection: a cohort study in Tehran | direction=unclear | directness=indirect | B2 | outcome=Immune and Inflammation; direction=unclear | finding=5 extracted claim(s); source-level direction is the coded finding | [bundle:47]
| Immune and Inflammation | Yingyounyong 2025: A study of booster dose influenza vaccination responses compared to standard dose in lupus patients: an open-labeled, randomized controlled study | direction=unclear | directness=direct | A1 | outcome=Immune and Inflammation; direction=unclear | finding=representative non-significant statistic P = 0.064; not treated as positive or negative directional support unless source direction is coded | [bundle:8]
| Longevity | Alotaibi 2026: Impact of Influenza Vaccination on Mortality and Major Cardiovascular Events in Adults with Cardiovascular Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials | direction=mixed | directness=review | B1 | outcome=Longevity; direction=mixed | finding=representative statistic P = 0.004; source-level statistic reported | [bundle:34]
| Longevity | Appel 2025: The Effect of Influenza Vaccination on Hospitalization and Mortality Among People With Dementia | direction=positive | directness=indirect | B2 | outcome=Longevity; direction=positive | finding=44 extracted claim(s); source-level direction is the coded finding | [bundle:16]
| Longevity | Hosseini 2026: Mortality and Morbidity Benefit After Influenza Vaccination in High Cardiovascular Risk Population: A Systematic Review and Meta-analysis. | direction=positive | directness=review | B1 | outcome=Longevity; direction=positive | finding=4 extracted claim(s); source-level direction is the coded finding | [bundle:49]
| Longevity | Incalzi 2024: Influenza vaccination for elderly, vulnerable and high-risk subjects: a narrative review and expert opinion | direction=null | directness=review | B2 | outcome=Longevity; direction=null | finding=2 extracted claim(s); source-level direction is the coded finding | [bundle:52]
| Longevity | Leung 2025: The effect of SARS-CoV-2 and influenza vaccination on endemic coronavirus-related mortality: A retrospective cohort study in Brazil | direction=positive | directness=indirect | B2 | outcome=Longevity; direction=positive | finding=representative statistic P < 0.001; source-level statistic reported | [bundle:36]
| Longevity | Liu 2025: Association between influenza vaccination and prognosis in patients with ischemic heart disease: A systematic review and meta-analysis of randomized controlled trials. | direction=positive | directness=review | B1 | outcome=Longevity; direction=positive | finding=7 extracted claim(s); source-level direction is the coded finding | [bundle:45]
| Longevity | Luo 2026: Impacts of delayed influenza vaccination on clinical outcomes in ICU-admitted patients with influenza: A retrospective cohort study | direction=null | directness=indirect | B2 | outcome=Longevity; direction=null | finding=representative non-significant statistic P = 0.838; not treated as positive or negative directional support unless source direction is coded | [bundle:7]
| Longevity | Streeter 2022: Influenza vaccination reduced myocardial infarctions in United Kingdom older adults: a prior event rate ratio study. | direction=positive | directness=review | B1 | outcome=Longevity; direction=positive | finding=4 extracted claim(s); source-level direction is the coded finding | [bundle:50]
| Mortality and Survival | Sun 2025: Effect of Current-Season-Only Versus Continuous Two-Season Influenza Vaccination on Mortality in Older Adults: A Propensity-Score-Matched Retrospective Cohort Study | direction=positive | directness=indirect | B2 | outcome=Mortality and Survival; direction=positive | finding=representative statistic P < 0.001; source-level statistic reported | [bundle:1]
| Safety and Comorbidity | Espersen 2025a: Electronic nudges to increase influenza vaccination uptake in younger and middle-aged individuals with atrial fibrillation: a prespecified analysis of the NUDGE-FLU-CHRONIC trial | direction=positive | directness=indirect | B2 | outcome=Safety and Comorbidity; direction=positive | finding=representative statistic P < 0.001; source-level statistic reported | [bundle:2]
| Safety and Comorbidity | Jiang 2025: Barriers to influenza vaccination in older adults with chronic diseases: Insights from a COM-B model–based meta-analysis | direction=null | directness=review | B2 | outcome=Safety and Comorbidity; direction=null | finding=31 extracted claim(s); source-level direction is the coded finding | [bundle:24]

## Key Findings

Key findings from source synthesis:

Manifest outcome-class count summary: Contextual Adjacent Evidence: admitted n=26 (mixed=2, null=13, positive=3, unclear=8); leading sources: Chen 2025, Wang 2025a, Wright 2025; Cardiometabolic: admitted n=10 (null=5, positive=2, unclear=3); leading sources: Wang 2025c, Wei 2026, Chiu 2025; Longevity: admitted n=8 (mixed=1, null=2, positive=5); leading sources: Luo 2026, Alotaibi 2026, Leung 2025; Dosing and Pharmacokinetics: admitted n=3 (null=1, unclear=2); leading sources: Wen 2025, Bonduelle 2025, Bukhbinder 2026; Safety and Comorbidity: admitted n=2 (null=1, positive=1); leading sources: Espersen 2025a, Jiang 2025. [bundle:2] [bundle:3] [bundle:5] [bundle:7] [bundle:10] [bundle:12] [bundle:15] [bundle:22] [bundle:24] [bundle:27] [bundle:31] [bundle:34] [bundle:36] [bundle:40]

Outcome-class key findings:

- Chen 2025: Impact of multifaceted health education on influenza vaccination health literacy in primary school students: a cluster; representative statistic P < 0.001; source-level statistic reported; outcome=Contextual Adjacent Evidence; direction=unclear; directness=direct; tier=A1. [bundle:5]
- Yingyounyong 2025: A study of booster dose influenza vaccination responses compared to standard dose in lupus patients: an open-labeled; representative non-significant statistic P = 0.064; not treated as positive or negative directional support unless source direction is coded; outcome=Immune and Inflammation; direction=unclear; directness=direct; tier=A1. [bundle:8]
- Wang 2025a: A cluster randomised trial of digital messaging nudges to improve influenza vaccination uptake in China; representative statistic P < 0.001; source-level statistic reported; outcome=Contextual Adjacent Evidence; direction=unclear; directness=direct; tier=A1. [bundle:10]
- Wright 2025: Effectiveness of a theory-informed intervention to increase care home staff influenza vaccination rates: a cluster; representative non-significant statistic P = .435; not treated as positive or negative directional support unless source direction is coded; outcome=Contextual Adjacent Evidence; direction=mixed; directness=direct; tier=A1. [bundle:12]
- Espersen 2025b: Relative Effectiveness of High-Dose Versus Standard-Dose Influenza Vaccination Against Hospitalizations and Deaths; representative statistic P < .001; source-level statistic reported; outcome=Frailty; direction=positive; directness=direct; tier=A1. [bundle:25]

Source-level findings by outcome class:

- Cardiometabolic: Wang 2025c (Influenza Vaccination and Short‐Term Risk of Stroke Among Elderly Patients With Chronic Comorbidities in a; representative statistic p < 0.05; source-level statistic reported; outcome=Cardiometabolic; direction=positive; directness=indirect; tier=B2); Wei 2026 (The benefits of influenza vaccination in patients with cardiovascular disease: a systematic review and meta-analysis; representative non-significant statistic p = 0.20; not treated as positive or negative directional support unless source direction is coded; outcome=Cardiometabolic; direction=unclear; directness=review; tier=B2); Chiu 2025 (Big data analysis of influenza vaccination and liver cancer risk in hypertensive patients: insights from a nationwide; representative statistic p < .001; source-level statistic reported; outcome=Cardiometabolic; direction=positive; directness=indirect; tier=B2). [bundle:15] [bundle:22] [bundle:27]
- Contextual Adjacent Evidence: Chen 2025 (Impact of multifaceted health education on influenza vaccination health literacy in primary school students: a cluster; representative statistic P < 0.001; source-level statistic reported; outcome=Contextual Adjacent Evidence; direction=unclear; directness=direct; tier=A1); Wang 2025a (A cluster randomised trial of digital messaging nudges to improve influenza vaccination uptake in China; representative statistic P < 0.001; source-level statistic reported; outcome=Contextual Adjacent Evidence; direction=unclear; directness=direct; tier=A1); Wright 2025 (Effectiveness of a theory-informed intervention to increase care home staff influenza vaccination rates: a cluster; representative non-significant statistic P = .435; not treated as positive or negative directional support unless source direction is coded; outcome=Contextual Adjacent Evidence; direction=mixed; directness=direct; tier=A1). [bundle:5] [bundle:10] [bundle:12]
- Dosing and Pharmacokinetics: Wen 2025 (Immunogenicity and safety of 1 versus 2 doses of quadrivalent-inactivated influenza vaccine in children aged 3–8 years; representative nominally statistically significant statistic p > .05; not treated as positive or negative directional support unless source direction is coded; outcome=Dosing and Pharmacokinetics; direction=unclear; directness=indirect; tier=B2); Bonduelle 2025 (Boosting effect of high-dose influenza vaccination on innate immunity among elderly; representative statistic P < 0.05; source-level statistic reported; outcome=Dosing and Pharmacokinetics; direction=unclear; directness=indirect; tier=B2); Bukhbinder 2026 (Risk of Alzheimer Dementia After High-Dose vs Standard-Dose Influenza Vaccination; 24 extracted claim(s); receipt-level direction is the coded finding; outcome=Dosing and Pharmacokinetics; direction=null; directness=indirect; tier=B2). [bundle:3] [bundle:31] [bundle:40]
- Frailty: Espersen 2025b (Relative Effectiveness of High-Dose Versus Standard-Dose Influenza Vaccination Against Hospitalizations and Deaths; representative statistic P < .001; source-level statistic reported; outcome=Frailty; direction=positive; directness=direct; tier=A1). [bundle:25]
- Immune and Inflammation: Yingyounyong 2025 (A study of booster dose influenza vaccination responses compared to standard dose in lupus patients: an open-labeled; representative non-significant statistic P = 0.064; not treated as positive or negative directional support unless source direction is coded; outcome=Immune and Inflammation; direction=unclear; directness=direct; tier=A1); Abbasian 2025 (Investigating the relationship between influenza vaccination and COVID-19 infection: a cohort study in Tehran; 5 extracted claim(s); receipt-level direction is the coded finding; outcome=Immune and Inflammation; direction=unclear; directness=indirect; tier=B2). [bundle:8] [bundle:47]
- Longevity: Luo 2026 (Impacts of delayed influenza vaccination on clinical outcomes in ICU-admitted patients with influenza: A retrospective; representative non-significant statistic P=0.838; not treated as positive or negative directional support unless source direction is coded; outcome=Longevity; direction=null; directness=indirect; tier=B2); Alotaibi 2026 (Impact of Influenza Vaccination on Mortality and Major Cardiovascular Events in Adults with Cardiovascular Disease: A; representative statistic p = 0.004; source-level statistic reported; outcome=Longevity; direction=mixed; directness=review; tier=B1); Leung 2025 (The effect of SARS-CoV-2 and influenza vaccination on endemic coronavirus-related mortality: A retrospective cohort; representative statistic p < .001; source-level statistic reported; outcome=Longevity; direction=positive; directness=indirect; tier=B2). [bundle:7] [bundle:34] [bundle:36]
- Mortality and Survival: Sun 2025 (Effect of Current-Season-Only Versus Continuous Two-Season Influenza Vaccination on Mortality in Older Adults: A; representative statistic p < 0.001; source-level statistic reported; outcome=Mortality and Survival; direction=positive; directness=indirect; tier=B2). [bundle:1]
- Safety and Comorbidity: Espersen 2025a (Electronic nudges to increase influenza vaccination uptake in younger and middle-aged individuals with atrial; representative statistic P < 0.001; source-level statistic reported; outcome=Safety and Comorbidity; direction=positive; directness=indirect; tier=B2); Jiang 2025 (Barriers to influenza vaccination in older adults with chronic diseases: Insights from a COM-B model–based meta-analysis; 31 extracted claim(s); receipt-level direction is the coded finding; outcome=Safety and Comorbidity; direction=null; directness=review; tier=B2). [bundle:2] [bundle:24]

Synthesis interpretation: These source-level findings connect risk-marker, mechanistic, and intervention-adjacent signals into follow-up hypotheses, not a clinical efficacy claim. Direct/interventional rows define the ceiling for applied interpretation; indirect prevalence, risk-association, mechanistic, protocol, and review rows define context and uncertainty. Representative coded source verdicts remain: Sun 2025: outcome=Mortality and Survival; direction=positive; directness=indirect; tier=B2; result=Effect of Current-Season-Only Versus Continuous Two-Season Influenza Vaccination on Mortality in Older Adults: A; finding=representative statistic p < 0.001; source-level statistic reported; claims=106; Espersen 2025a: outcome=Safety and Comorbidity; direction=positive; directness=indirect; tier=B2; result=Electronic nudges to increase influenza vaccination uptake in younger and middle-aged individuals with atrial; finding=representative statistic P < 0.001; source-level statistic reported; claims=97; Wen 2025: outcome=Dosing and Pharmacokinetics; direction=unclear; directness=indirect; tier=B2; result=Immunogenicity and safety of 1 versus 2 doses of quadrivalent-inactivated influenza vaccine in children aged 3–8 years; finding=representative nominally statistically significant statistic p > .05; not treated as positive or negative directional support unless source direction is coded; claims=93; Guo 2025: outcome=Cardiometabolic; direction=unclear; directness=indirect; tier=B2; result=Estimating cardiovascular effects of influenza vaccination in older adults: a target trial emulation using proximal; finding=76 extracted claim(s); receipt-level direction is the coded finding; claims=76. The bounded conclusion follows from source direction, outcome class, evidence tier, and directness rather than from source count alone. Publication-year note: citation years follow the manifest metadata; when DOI/PubMed dates differ, the source should be treated as bibliographic/in-press metadata and not used for year-specific claims. [bundle:1] [bundle:2] [bundle:3] [bundle:4]

## Results

**Outcome-class note:** Contextual Adjacent Evidence denotes background, boundary-condition, or adjacent-outcome sources. It is not pooled with direct outcome evidence; these sources bound scope, safety, methods, and translation rather than serving as equal-weight support for the main efficacy claim.

| Evidence domain | Corpus slice | Strongest signal | Directness | Main limitation |
|---|---|---|---|---|
| Influenza Vaccination Effects / Contextual Adjacent Evidence | n=26; claims=745 | significant source statistic in 13/26 sources; receipt-level direction coded null | 10 direct; 13 indirect; 3 review | limited corpus depth in this outcome class |
| Influenza Vaccination Effects / Cardiometabolic | n=10; claims=396 | significant source statistic in 2/10 sources; receipt-level direction coded null | 4 indirect; 1 protocol; 5 review | limited corpus depth in this outcome class |
| Influenza Vaccination Effects / Longevity | n=8; claims=163 | positive signal in 5/8 sources | 3 indirect; 5 review | limited corpus depth in this outcome class |
| Influenza Vaccination Effects / Dosing and Pharmacokinetics | n=3; claims=131 | significant source statistic in 2/3 sources; receipt-level direction coded unclear | 3 indirect | limited corpus depth in this outcome class |
| Influenza Vaccination Effects / Immune and Inflammation | n=2; claims=64 | significant source statistic in 1/2 sources; receipt-level direction coded unclear | 1 direct; 1 indirect | limited corpus depth in this outcome class |
| Influenza Vaccination Effects / Safety and Comorbidity | n=2; claims=128 | significant source statistic in 1/2 sources; receipt-level direction coded unclear | 1 indirect; 1 review | limited corpus depth in this outcome class |
| Influenza Vaccination Effects / Frailty | n=1; claims=31 | positive signal in 1/1 sources | 1 direct | single-source slice; hypothesis-generating |
| Influenza Vaccination Effects / Mortality and Survival | n=1; claims=106 | positive signal in 1/1 sources | 1 indirect | single-source slice; hypothesis-generating |

**Source-context map:** Source-title contexts are separated for interpretation and are not pooled as one clinical effect.
- Infectious-disease and immunology context: 52 sources; significant source statistic in 22/52 sources; receipt-level direction coded null.
- Oncology and cancer context: 1 sources; positive signal in 1/1 sources.

### Results Summary

- Contextual Adjacent Evidence: n=26; claims=745; no extracted directional signal in 13/26 sources | directness: 10 direct; 13 indirect; 3 review; main limitation: directionally heterogeneous.
- Cardiometabolic: n=10; claims=396; no extracted directional signal in 5/10 sources | directness: 4 indirect; 5 review; 1 protocol; main limitation: no direct clinical anchor.
- Longevity: n=8; claims=163; benefit signal in 5/8 sources | directness: 3 indirect; 5 review; main limitation: no direct clinical anchor.
- Dosing and Pharmacokinetics: n=3; claims=131; mixed signal in 2/3 sources | directness: 3 indirect; main limitation: no direct clinical anchor.
- Immune and Inflammation: n=2; claims=64; mixed signal in 2/2 sources | directness: 1 direct; 1 indirect; main limitation: population and endpoint heterogeneity.
- Safety and Comorbidity: n=2; claims=128; mixed signal in 1/2 sources | directness: 1 indirect; 1 review; main limitation: no direct clinical anchor.

### Cardiometabolic Outcomes

Ten included sources populate the cardiometabolic outcome class, spanning adults, older adults, type 1 and type 2 diabetes populations, hypertensive cohorts, coronary artery disease (CAD) patients, and elderly stroke survivors, with one protocol-only entry for a paediatric type 1 diabetes trial. The corpus combines four reviews or umbrella syntheses (Yang 2024, Tadount 2025, Jin 2026, Wei 2026), four indirect observational cohort studies (Guo 2025, Wang 2025c, Chiu 2025, Yang 2025), one randomised placebo-controlled trial (Dehesh 2025), and one trial protocol (Pedersen 2024). Endpoint targets across these sources include all-cause mortality, major adverse cardiovascular events (MACE), myocardial infarction (MI), stroke, intensive care unit (ICU) admission, liver cancer incidence among hypertensive patients, and vaccination coverage among diabetic patients. Directness is mixed: Dehesh 2025 functions as a clinical RCT, Wang 2025c and Yang 2025 provide population-based cohort data with adjustment for demographic and comorbidity confounders, and the umbrella reviews (Tadount 2025, Jin 2026, Wei 2026) integrate across heterogeneous source designs rather than enrolling a primary population. [bundle:4] [bundle:9] [bundle:11] [bundle:15] [bundle:17] [bundle:18] [bundle:22] [bundle:27] [bundle:39] [bundle:42]

Quantitative findings diverge by study type and risk stratum.

Mechanistically, the umbrella-review and meta-analytic sources (Tadount 2025, Jin 2026, Wei 2026) propose that averted or attenuated respiratory infection reduces the systemic inflammatory and prothrombotic surges that precipitate plaque rupture and arrhythmia in susceptible hosts. Preclinical and indirect human evidence summarised by Jin 2026 highlights a self-controlled case-series observation that laboratory-confirmed influenza within the preceding 7 days is associated with elevated acute vascular risk, providing biological plausibility for vaccination-mediated protection. [bundle:11] [bundle:17] [bundle:22]

Observational and quasi-experimental studies describe the absolute coverage levels against which these interventions are tested.

Mechanistically, the corpus frames coverage as the proximal behavioural substrate on which clinical protection depends.

Several entries in the corpus are protocols or quasi-experimental designs whose endpoint is mechanistic rather than behavioural, and they are catalogued as direct-RCT or indirect-cohort depending on whether they enrol a clinical population.

Preclinical and observational data extend the mechanistic substrate from acute cardiopulmonary protection to long-horizon neurodegeneration risk.

### Dosing and Pharmacokinetics Outcomes

Three observational cohorts in the corpus evaluate dose-related effects of influenza vaccination, with two addressing standard versus high-dose formulations in older adults and one comparing single versus two-dose schedules in younger children. Bonduelle 2025 assessed the boosting effect of high-dose influenza vaccination on innate immunity markers among elderly recipients, measuring post-vaccination innate immune readouts rather than clinical infection endpoints. All three studies share an indirect-directness label and rely on observational rather than randomized designs, which constrains causal inference about dose magnitude. [bundle:40]

Mechanistically, the three dosing studies point toward distinct substrate layers rather than converging on a single biological pathway. Bukhbinder 2026 occupies a different mechanism layer: rather than measuring acute immunogenicity, the cohort tests whether chronic exposure to a higher antigen dose translates into downstream neurodegenerative risk reduction over months 1–25 postvaccination. The mechanistic substrate thus spans innate-boosting, recall-antigen priming, and long-horizon neuroprotection hypotheses, each tied to a separate source and not directly comparable. [bundle:31]

Within-corpus tensions across these three dose-related studies are best characterized as endpoint-dependent rather than as a directional conflict over vaccination itself. Bonduelle 2025 carries an unclear effect direction despite multiple P < 0.05 (Bonduelle 2025) markers, again reflecting that the innate-boosting signal does not cleanly map onto a clinical-outcome directional verdict. The three sources thus disagree on whether dose magnitude produces a clear net positive, null, or unclear effect, with the disagreement driven by endpoint choice (immunogenicity vs innate readouts vs dementia incidence) rather than by contradictory findings within a shared endpoint. The endpoint architecture positions frailty score as a stratifying variable against hospitalizations and deaths rather than as an independent primary endpoint, which constrains interpretation to relative effectiveness rather than absolute frailty modification. [bundle:40]

### Immune and Inflammation Outcomes

One clinical RCT in the corpus evaluated booster-dose versus standard-dose influenza vaccination in lupus patients, with HAI titers and upper-respiratory tract infection (URTI) incidence as the primary mechanistic/clinical endpoints (Yingyounyong 2025). The trial enrolled adults with systemic lupus erythematosus and randomized participants to a booster-dose (BD) or standard-dose (HI) schedule. The HAI titer rates of ≥ 1:160 cut point were increased in all strains after BD, approaching 100%, similar to the HI group. URTI incidence is the secondary clinical readout, allowing the immunological gain of boosting to be anchored to a patient-facing outcome. [bundle:8]

The reported p-values from the Yingyounyong 2025 RCT cluster around modest immunological separation with downstream clinical signal. After BD, the HAI titer rates of ≥ 1:160 cut point were increased in all strains, approaching 100%, similar to the HI group; the between-arm comparison yielded P = 0.064 for the seroconversion endpoint and P = 0.008 for the URTI-related clinical endpoint, indicating a stronger signal on the clinical than the immunological readout. Because these numerics are reported exactly as printed in the source, the evidence synthesis (Per-Study Endpoint Evidence) carries the full study × p-value tuple and the prose here only references the two anchor values rather than re-listing them. [bundle:8]

Mechanistically, the booster-dose schedule appears to drive HAI titers toward the upper bound of the assay in a population whose baseline immune responsiveness is altered by immunosuppressive therapy, which is consistent with the broader mechanistic human literature on antigen-dose-dependent humoral recall. The clinical URTI signal (P = 0.008) maps onto the same pathway: higher post-vaccination titers are the proximate substrate for the observed reduction in symptomatic respiratory events. Because the only immune-class source in the corpus is this single RCT, the mechanistic substrate underlying this functional finding is necessarily drawn from one trial rather than triangulated across multiple mechanistic human studies.

Within-corpus tensions on the immune axis are limited because the corpus contributes a single direct RCT and no non-orthogonal pair is recorded in the cross-study disagreement map for this outcome class. , and the original cohort framework leaves the endpoint defined entirely in terms of COVID-19 acquisition rather than any canonical influenza-specific immunological readout. No follow-up duration, dose description, or randomisation schedule is supplied in the available source, which constrains the granularity of quantitative description in the prose.

Quantitatively, the source reports that after adjustment for confounding variables, the calculated Hazard Ratio indicated that influenza vaccination has no significant effect on the outcome variable, and the direction of the effect is recorded as unclear in the curated summary (Abbasian 2025). No p-value, 95% confidence interval, hazard ratio point estimate, or sample size is recorded in the source, so the prose deliberately avoids substituting any canonical numeric; the only quantitative anchor is the qualitative descriptor that the association was non-significant after covariate adjustment, with the effect direction flagged as unclear rather than positive or inverse. [bundle:47]

Mechanistically, an indirect observational cohort finding of no measurable hazard modification sits awkwardly alongside the well-established immunological rationale for influenza vaccination, namely the elicitation of strain-specific neutralising antibodies and T-cell responses documented across decades of clinical RCT work, but the corpus does not contain a mechanistic human substudy that directly links Abbasian's clinical endpoint to a measured cellular or humoral correlate. Because only an indirect, observationally derived human signal is available for this outcome class, the mechanistic substrate underlying this functional finding cannot be elaborated from the sources themselves and is left for future bundles that pair serological endpoints with the same cohort design.

Because Abbasian 2025 is the sole source mapped to immune inflammation in the curated corpus, there is no within-class tension to surface, and the cross-class synthesis handles all disagreements at the outcome-class boundary rather than within this section; reviewers seeking the comparative numerics for Abbasian versus the longevity, cardiometabolic, and contextual-other outcome classes should consult the evidence synthesis (Per-Study Endpoint Evidence), which carries the per-study × p-value tuples and any future sources that populate this category will be appended to the same table without disturbing the present prose. [bundle:47]

### Longevity Outcomes

The longevity evidence base spans both observational cohorts and aggregated reviews. Hosseini 2026 is a systematic review and meta-analysis pooling high cardiovascular-risk trials and reports that influenza vaccination significantly reduced all-cause mortality (HR = 0.72; 95% CI: 0.63 to 0.82) and cardiovascular mortality (HR = 0.77; 95% CI as quoted in the source). These two sources anchor the upper bound of the longevity signal in adults. [bundle:49]

Cohort-level signals in vulnerable subgroups complement the pooled review evidence. By contrast, the clinical RCT substrate behind these observational effects — namely the trials synthesized by Alotaibi 2026, Liu 2025, and Hosseini 2026 — converges on the same directional finding for cardiovascular and all-cause mortality endpoints in adults. Preclinical and mechanistic human studies do not directly enter this longevity subsection, so the mechanistic substrate underlying these functional findings is inferred from the cardiovascular pathway literature covered by those three reviews. [bundle:34] [bundle:45] [bundle:49]

### Mortality and Survival Outcomes

In an observational cohort using 2017–2019 data from the Center for Disease Control and Prevention of Shenzhen, Guangdong, China, Sun 2025 applied propensity-score matching to compare current-season-only versus continuous two-season influenza vaccination in older adults. The source characterizes the study design as an observational cohort with an indirect-to-mortality endpoint structure, and it is positioned as the single mortality-survival entry in the curated corpus. The relevant comparison contrasts individuals vaccinated in the current season only against those vaccinated across two consecutive seasons, with the matched cohort forming the analytic base for downstream survival contrasts. [bundle:1]

The source lists the following exact p-values for the mortality-related contrasts: P < 0.001, P = 0.017, P = 0.130, P = 0.045, P = 0.029, P = 0.008, and P = 0.001. Because Sun 2025 is the only mortality-survival source in the corpus, no within-class corroboration is available and the seven p-values reported here are reproduced verbatim from the source entry. Effect-direction annotation in the source is recorded as positive, indicating that the continuous two-season regimen is associated with favorable mortality contrasts relative to current-season-only vaccination in this propensity-score-matched older-adult cohort. No effect sizes, hazard ratios, or sample sizes are recorded in the source beyond these p-values. [bundle:1]

Mechanistically, an indirect outcome-class flag in this source implies that the mortality signal is downstream of cardiovascular, respiratory, or infection-related intermediates rather than a direct vaccine–mortality assay. The source is anchored in a clinical observational cohort rather than a randomized efficacy trial, so the pathway connecting vaccination to survival likely operates through reduced incident influenza, fewer influenza-triggered cardiopulmonary decompensations, and attenuated frailty-domain stressors in the older-adult population. Within the broader corpus, no mechanistic human or preclinical sources were provided under the mortality survival outcome class, so the substrate remains inferential pending source-supported corroboration.

Because Sun 2025 is the sole mortality-survival source in the curated set, within-corpus tensions cannot be enumerated for this outcome class — the cross-study disagreement map records no non-orthogonal pairs and no second mortality-survival entry is supplied for direct contrast. The source’s effect direction field is recorded as positive, but the indirect outcome-class flag and the single-study base mean that the magnitude and boundary conditions of the survival benefit cannot be triangulated against another human dataset in the present corpus. The single-p-value contrast set (with one non-significant entry at P = 0.130 among otherwise significant contrasts) is reported exactly as logged and should be interpreted as one observational-cohort signal rather than a class-level consensus. [bundle:1]

### Safety and Comorbidity Outcomes

NUDGE-FLU-CHRONIC, evaluated in a prespecified secondary analysis by Espersen 2025a, is the principal within-corpus trial informing whether electronic behavioural nudges shift influenza vaccination uptake among adults (younger and middle-aged strata) who have atrial fibrillation, a population whose comorbidity burden materially elevates influenza-related morbidity risk. The trial randomized citizens within a nationwide registry platform to receive electronic reminders, and the prespecified analysis examined uptake differential between nudge recipients and usual-care controls stratified by age band and AF status, with uptake captured at the end of the influenza immunisation window. Espersen 2025a reports p-values of P < 0.001 and P = 0.027 for the two strata of interest, supporting a positive nudge effect on vaccination coverage. Directness is classified as indirect for the broader safety/comorbidity question because the primary endpoint is behavioural uptake rather than a downstream comorbidity event. [bundle:2]

Quantitative findings from Espersen 2025a anchor the within-corpus effect estimate for this outcome class. The two strata-comparison statistics — P < 0.001 in the primary contrast and P = 0.027 in the subgroup interaction — are reported exactly as they appear in the source and indicate that the behavioural intervention meaningfully increased vaccination uptake relative to control; no between-strata effect direction is flagged in the source (effect direction: unclear), so this synthesis cannot assign the magnitude a definite polarity at the subgroup level beyond the reported interaction p-value. Detailed trial-level effect sizes, including absolute percentage-point increases in uptake and number-needed-to-nudge, are carried in the evidence synthesis rather than restated here, since the evidence synthesis (Per-Study Endpoint Evidence) preserves every per-study numeric tuple in its original form. [bundle:2]

Mechanistically, the safety/comorbidity rationale for influenza vaccination in older adults and chronic-disease populations operates through reduction in pathogen-driven decompensation of cardiac, pulmonary, and metabolic reserve, and Jiang 2025 supplies the corresponding behavioural-science substrate for why uptake itself is variable. Together the two sources describe a coherent causal chain: behavioural barriers (COM-B) raise the case for electronic nudges (NUDGE-FLU-CHRONIC) in comorbidity-bearing adults. [bundle:24]

Within-corpus tensions for the safety comorbidity class pivot on the directional ambiguity in Espersen 2025a (effect direction: unclear) set against the behavioural-barrier finding in Jiang 2025. Because Espersen 2025a reports subgroup-level direction as unclear despite stratum-level statistical significance, the corpus does not adjudicate whether nudge effects on uptake are uniform across AF-severity bands; Jiang 2025's COM-B meta-analysis is consistent with non-uniform uptake but cannot itself resolve the trial's stratified signal. The two sources thus present complementary — not contradictory — perspectives: a clinical RCT (NUDGE-FLU-CHRONIC) whose behavioural endpoint moves toward higher uptake, and a mechanistic human study (Jiang 2025) whose barriers explain residual non-uptake among older adults with chronic disease. [bundle:2] [bundle:24]

### Contextual Adjacent Evidence Outcomes

McConeghy 2025, an indirect observational cohort in US Medicare-certified nursing homes (mean daily census ≥ 50 long-stay residents, ≥ 100 days of residence), compared recombinant versus egg-based quadrivalent vaccines. [bundle:32]

Within-corpus tensions on this mechanistic bundle again trace to directness rather than to opposing clinical signals: every direct-RCT or direct-protocol source (Wang 2024, Xie 2024, Zhang 2024, Lin 2024, Hansen 2025, Wright 2025, Chen 2025, Li 2025, Katangwe-Chigamba 2025, Wang 2025a) sits in tension with each of the indirect or review sources above. The absence of a unified clinical-efficacy endpoint — uptake in some studies, antibody fold-rise in others, dementia incidence in reviews — is the principal reason these source pairs cannot be adjudicated head-to-head. [bundle:5] [bundle:10] [bundle:12] [bundle:28] [bundle:33] [bundle:38] [bundle:41] [bundle:43] [bundle:44] [bundle:48]

Contextual Adjacent Evidence remains a separate Results slice for Influenza Vaccination Effects (n=26; claims=745; significant source statistic in 13/26 sources; source-level direction coded null; 10 direct; 13 indirect; 3 review; limited corpus depth in this outcome class) and is not pooled into adjacent endpoint classes. Source-level findings are:
- Chen 2025 (Impact of multifaceted health education on influenza vaccination health literacy in primary school students: a cluster; representative statistic P < 0.001; source-level statistic reported; outcome=Contextual Adjacent Evidence; direction=unclear; directness=direct; tier=A1). [bundle:5]
- Wang 2025a (A cluster randomised trial of digital messaging nudges to improve influenza vaccination uptake in China; representative statistic P < 0.001; source-level statistic reported; outcome=Contextual Adjacent Evidence; direction=unclear; directness=direct; tier=A1). [bundle:10]
- Wright 2025 (Effectiveness of a theory-informed intervention to increase care home staff influenza vaccination rates: a cluster; representative non-significant statistic P = 0.435; not treated as positive or negative directional support unless source direction is coded; outcome=Contextual Adjacent Evidence; direction=mixed; directness=direct; tier=A1). [bundle:12]
- Katangwe-Chigamba 2025 (Process evaluation of the flucare cluster randomised controlled trial: assessing the implementation of a behaviour; representative statistic P = 0.045; source-level statistic reported; outcome=Contextual Adjacent Evidence; direction=positive; directness=direct; tier=A1). [bundle:43]

Direction reconciliation: source-level null or unclear coding is conservative claim-level coding. Significant but polarity-unsigned statistics remain unclear unless the extraction records a positive, negative, or mixed effect direction.

### Frailty Outcomes

, with the precise mapping of each value to specific between-frailty-stratum comparisons reserved to the evidence synthesis [Espersen 2025b]. Because the trial measured relative effectiveness rather than change in frailty itself, the borderline P = 0.07 and P = 0.052 values likely correspond to interaction or stratum-level contrasts rather than to within-person frailty trajectories. Quantitative findings should therefore be read as effect modification evidence rather than as evidence of vaccine-induced frailty modification. [bundle:25]

Mechanistically, this clinical RCT finding aligns with a broader literature in which influenza vaccination has been proposed to attenuate inflammation-driven functional decline in older adults, plausibly through reduced respiratory infection burden and downstream catabolic insults [Espersen 2025b]. The mechanistic substrate underlying this functional finding would be expected to operate most strongly in those with the least physiologic reserve, providing a rationale for the frailty-stratified subgroup design. However, the source itself does not supply direct mechanistic biomarker data, and any mechanistic narrative depends on external inference rather than on source-traced within-study measurements. [bundle:25]

Within-corpus tensions for this outcome class are inherently constrained because a single source (Espersen 2025b) carries the entire frailty evidence base, leaving no within-class disagreement to surface in this section. The cross-study disagreement map records no same-outcome non-orthogonal pairs for frailty, consistent with the singleton-source structure. Future updates expanding the source pool to include other frailty-stratified influenza vaccine trials would be needed before intra-class tensions can be characterized. [bundle:25]

Frailty remains a separate Results slice for Influenza Vaccination Effects (n=1; claims=31; positive signal in 1/1 sources; 1 direct; single-source slice; hypothesis-generating) and is not pooled into adjacent endpoint classes. Source-level findings are:
- Espersen 2025b (Relative Effectiveness of High-Dose Versus Standard-Dose Influenza Vaccination Against Hospitalizations and Deaths; representative statistic P < 0.001; source-level statistic reported; outcome=Frailty; direction=positive; directness=direct; tier=A1). [bundle:25]

## Cross-Domain Synthesis

The most load-bearing tension in this corpus is the divergence between surrogate/behavioral uptake outcomes and hard clinical endpoints. A dense cluster of direct randomized trials and quasi-experimental studies (Wang 2024, Xie 2024, Chen 2025, Hansen 2025, Li 2025, Wright 2025, Katangwe-Chigamba 2025, Wang 2025a) measures behavioral endpoints (vaccination uptake, intentions, knowledge, text-message responsiveness) in adult and pediatric populations, whereas the clinical outcome literature (Sun 2025 mortality, Appel 2025 longevity, Leung 2025 longevity, Wei 2026 cardiometabolic) is dominated by indirect observational or review-level evidence. The temptation is to fuse the two: behavioral RCTs reporting positive uptake signals are routinely cited as if they imply mortality or cardiovascular benefit. They do not. The Ioannidis 2005 surrogate-endpoint caveat (methodological reference) is directly applicable: improvements in vaccination intent, literacy, or text-nudge responsiveness are surrogates for population-level coverage, not for hard clinical endpoints. The boundary condition is straightforward — behavioral RCT evidence supports coverage-strategy claims; mortality, hospitalization, and MACE claims must rest on direct or near-direct evidence (Espersen 2025b for high-dose vs standard-dose frailty-stratified hospitalizations, Alotaibi 2026 for cardiovascular RCT meta-analysis). The evidence that would resolve this tension is a cluster-randomized uptake trial with linked registry-based mortality or cardiovascular follow-up — none of the sources describe such a design. [bundle:1] [bundle:5] [bundle:10] [bundle:12] [bundle:16] [bundle:22] [bundle:25] [bundle:28] [bundle:33] [bundle:34] [bundle:36] [bundle:38] [bundle:43] [bundle:48]

Another cross-domain tension pits the cardiometabolic evidence base against the mechanistic/biomarker literature. Against this stands the mechanistic/biomarker RCT cluster (Yingyounyong 2025 lupus booster-dose immunogenicity, Bonduelle 2025 high-dose innate-immunity boosting, Wen 2025 pediatric dose-count immunogenicity), which measures immune-response surrogates rather than clinical events. These two evidence streams cannot be reported as a single causal sentence without explicit hedging — the cardiometabolic signal is observational/review-level and prone to healthy-vaccinee bias, while the biomarker RCTs do not measure the hard outcomes they are sometimes invoked to support. The trial that would resolve this gap is a placebo-controlled cardiovascular outcomes RCT in frail older adults; Dehesh 2025 (IVCAD) and Zhang 2024 (PANDA II) are protocol-stage, not yet results-stage. [bundle:3] [bundle:8] [bundle:39] [bundle:40] [bundle:44]

Another tension is the divergence between longevity/geriatric outcomes and acute-care outcomes within the same intervention class. The mechanism-level reason these may disagree: chronic-disease modification (dementia, cardiovascular) operates over multi-year horizons and is plausibly detectable in observational cohorts, whereas short-horizon ICU mortality is dominated by acute-pathophysiology drivers that vaccination within 14 days of admission cannot reverse. The boundary condition is therefore temporal — chronic-disease and dementia signals are consistent with multi-year immunomodulatory mechanisms, while acute ICU outcomes are not. The trial that would resolve this is a long-horizon randomized primary-prevention trial with dementia and all-cause mortality co-primary endpoints; none of the sources describe one.

Another tension concerns the comparison between direct RCTs measuring behavioral/intermediate endpoints and indirect observational studies measuring clinical endpoints — a direct/indirect asymmetry that the cross-study disagreement map flags as severity-3 across nearly every pairwise comparison involving the behavioral RCT cluster. Direct trials (Wang 2024, Xie 2024, Chen 2025, Hansen 2025, Li 2025, Wright 2025, Katangwe-Chigamba 2025, Wang 2025a) randomize at the cluster or individual level but measure uptake, intention, or literacy — endpoints that are necessary but not sufficient for clinical benefit. Indirect observational studies and reviews (Hu 2024, Mora 2025, Szilagyi 2025, Wang 2025b, Alshagrawi 2025, Chaves 2026, Andrew 2004, Krishnan 2026, McConeghy 2025, Fortunato 2025, Blandi 2026, Rocinova 2026, Pagkozidis 2026) measure coverage, hospitalization, or mortality in real-world settings where randomization is absent. Even there, the between-frailty-stratum interaction terms trend toward but do not achieve significance (P = 0.052), so the boundary condition remains only partially defined. The trial that would resolve this is a pragmatic RCT randomizing at the system level with registry-based clinical follow-up; the Hansen 2025 InfluSMS protocol gestures toward this design but reports no clinical outcomes. [bundle:5] [bundle:6] [bundle:10] [bundle:12] [bundle:13] [bundle:14] [bundle:19] [bundle:20] [bundle:23] [bundle:26] [bundle:28] [bundle:29] [bundle:32] [bundle:33] [bundle:37] [bundle:38] [bundle:43] [bundle:46] [bundle:48] [bundle:51] [bundle:53]

Another tension sits within the safety and comorbidity class: the nudging/uptake literature and the safety/barrier literature use the same exposure (vaccination) but measure different downstream consequences, and their effect-direction labels disagree. Espersen 2025a (NUDGE-FLU-CHRONIC prespecified atrial fibrillation analysis) reports electronic-nudge effects on uptake in younger and middle-aged adults with atrial fibrillation (P < 0.001, P = 0.027), framed as a positive safety-relevant intervention. The direct/indirect asymmetry is acute here: the RCT (Espersen 2025a) measures uptake, while the meta-analytic review (Jiang 2025) measures barriers-to-uptake rather than clinical safety. The two cannot be merged into a safety claim. The boundary condition: nudging trials establish that behavioral interventions increase uptake in selected populations, while barrier meta-analyses establish that motivation/opportunity/capability gaps predict non-uptake; neither establishes clinical safety, and neither source reports a safety event rate above background. [bundle:2] [bundle:24]

The included evidence base contains direct, indirect evidence, so the manuscript should not collapse mechanistic plausibility and clinical efficacy into one verdict.

The framework is useful here because the matrix contains mechanism-vs-clinical, null-vs-positive tensions that can otherwise be mistaken for simple inconsistency.

A falsifying test would be a direct clinical trial in the same dosing context that shows concordant movement across pathway markers, functional endpoints, and distal clinical outcomes; discordance across those layers would preserve the framework.

This is a paper-level organizing claim, not an added source: it can guide interpretation only where the underlying evidence record already supplies support.

### Boundary-condition synthesis

Interpreting the cross-domain evidence requires treating each domain as
part of a boundary-condition map rather than as a single pooled effect. Direct human findings set the clinical perimeter; mechanistic findings
explain plausible pathways; indirect findings identify where transfer
across populations, time horizons, or measurement systems remains
uncertain. This separation is important because evidence can be valid
within one outcome domain while remaining weak support for another. The synthesis therefore gives priority to source-traced clinical
findings when making patient-facing claims, uses mechanistic evidence
to explain why effects might diverge, and treats discordance as a
signal about applicability rather than as a reason to average unlike
endpoints together.

## Discussion

**Thesis:** Across 53 curated reference papers, the evidence base for Influenza shows a context-dependent profile. Positive signals appear in: longevity, cardiometabolic. Null findings dominate: contextual other, cardiometabolic. The synthesis surfaces cross-study disagreements across outcome classes — see Cross-Domain Synthesis. The Influenza broad aging-related case as currently constituted is incomplete: mechanistic plausibility coexists with mixed or sparse human-RCT evidence, and the boundary conditions remain to be established. This position is bounded by the included sources and does not imply clinical efficacy beyond the evidence profile.

The interpretation remains cautious, limited, and context-dependent because the accepted evidence spans different populations, outcomes, and evidence tiers.

### Evidence Summary

The evidence base for this synthesis comprises 53 included sources. By directness, the breakdown is: indirect (n=26), review (n=14), direct (n=12), protocol (n=1). 25 of 53 sources carry at least one p-value in their bound claims, providing the quantitative basis for the effect-direction conclusions argued above. The source-tier mapping matters because direct interventional hard-endpoint trials, indirect interventional hard-endpoint evidence, reviews, and mechanistic papers carry different interpretive weight.

Populations covered span 4 distinct summaries across the source set: frail / sarcopenic adults; older adults; type 2 diabetes patients; adults. This cross-population view is the evidentiary backstop for any claim about generalizability in the narrative discussion above. Where the paper argues a boundary condition by population, this enumeration documents which sources the boundary draws from.

### Interpretation constraints

The discussion interprets evidence boundaries rather than converting every extracted result into a recommendation. The corpus contains heterogeneous designs, populations, follow-up windows, and measurement strategies, so the central question is whether findings travel across contexts without losing their meaning. Clinical directness, outcome proximity, consistency of effect direction, and biological plausibility are therefore weighed together. Where those features align, the synthesis may support stronger inference; where they diverge, the paper keeps the conclusion conditional and treats the gap as a research-design problem for future work.

The source set also warrants a cautious distinction between statistical signal and aging relevance. A result can be numerically strong while remaining indirect for healthspan, frailty, disability, cognition, or mortality. Conversely, a mechanistic result can be consistent with an aging hypothesis while remaining limited as clinical evidence. This is why evidence tier, directness, outcome class, and effect direction are interpreted separately.

The most decision-relevant uncertainty is context-dependent. If direct human evidence clusters around the same outcome class, the synthesis treats that cluster as the strongest basis for practical inference. If the signal appears only in reviews, indirect cohorts, preclinical models, or mixed populations, the paper marks the claim as preliminary. If the matrix contains disagreements inside the same outcome class, the safer reading is not that one paper cancels another, but that eligibility, dose, comparator, endpoint definition, or follow-up duration might be controlling the observed effect. Those unresolved modifiers remain to be tested rather than assumed away.

The key interpretive question is not whether the topic looks promising; it is whether the strongest claim stays inside what the sources can support. This anchor therefore avoids adding new empirical claims. It summarizes the evidence structure already present in the corpus: how many sources were accepted, how those sources were tiered, how often statistical values were available, and which population summaries were documented. That keeps the Discussion section tied to the source record when the evidence base is broad but uneven.

The resulting stance is deliberately conservative. Positive signals are described as suggestive unless they are supported by direct, clinically proximate, source-traced sources. Null or mixed signals are not discarded; they define boundary conditions. Mechanistic findings are used to explain plausible pathways, not to substitute for outcome evidence. Safety and tolerability signals remain part of the interpretation even when efficacy signals dominate the narrative. This cautious framing prevents a dense corpus from becoming an overconfident manuscript.

This section also constrains how readers should use the paper. It is not a treatment guideline, a pooled efficacy estimate, or a claim that all source classes have equal evidentiary weight. It is a structured map of what the current corpus can and cannot justify. The strongest claims should come from direct human sources with traceable numerics and aligned outcomes. Weaker claims should remain explicitly limited to hypothesis generation, mechanism explanation, or corpus-gap identification. When future retrieval adds new sources, the interpretation can change without changing the evidentiary standard. The most useful reading is therefore comparative: which outcomes have direct human support, which outcomes are inferred from adjacent disease populations, and which outcomes remain primarily mechanistic.

Accordingly, the practical conclusion remains bounded by replication, population fit, and endpoint fit. A result that appears robust in one subgroup might not transfer to another subgroup with different baseline risk, adherence, comparator choice, or outcome ascertainment. A result that is consistent with biological plausibility might still be limited by short follow-up or indirect measurement. These caveats are not decorative hedges; they are the conditions under which the synthesis remains reproducible, falsifiable, and safe to reuse across topics. The anchor also states what the paper does not know: whether longer follow-up, different eligibility criteria, stronger adherence, or more clinically proximate endpoints would change the synthesis. That uncertainty should remain visible in every topic until the source set directly resolves it, and it should keep downstream conclusions provisional when the corpus is broad but still uneven across designs, outcomes, or populations.

**Resolution criteria:** This thesis should be revised if larger direct human studies, prespecified endpoints, longer follow-up, or consistent cross-outcome effect directions contradict the current evidence profile.

## Limitations

**Verification note:** Reference-only or no-abstract records are treated as verification-limited context, not as equal-weight support for the main claim.

The curated corpus contains no long-term, placebo-controlled randomized trial with hard endpoints (all-cause mortality, cardiovascular death, hospitalization for influenza or pneumonia, or stroke) in non-diabetic community-dwelling adults younger than 60. The mortality and cardiovascular claims that anchor the cardiometabolic and longevity signals are derived entirely from observational cohorts (Sun 2025; Leung 2025) and from systematic reviews that aggregate such cohorts (Wei 2026; Hosseini 2026; Alotaibi 2026; Streeter 2022; Liu 2025; Tadount 2025). Headline conclusions about cardiovascular event reduction (MACE) or all-cause mortality therefore extend beyond what the in-corpus randomized evidence can adjudicate, particularly for adults under 65 without established cardiovascular disease. [bundle:1] [bundle:11] [bundle:22] [bundle:34] [bundle:36] [bundle:45] [bundle:49] [bundle:50]

Several clinically-relevant outcomes are touched by only a single source and therefore cannot be replicated within the corpus. Effect-direction replication is not available for any of these endpoints within the present evidence base, so single-trial signals should be treated as hypothesis-generating rather than confirmatory.

Population specificity is uneven across the included studies and constrains external validity. Estimates obtained in one healthcare system or demographic stratum therefore cannot be assumed to transport unchanged to other contexts.

Endpoint scope is narrower than the headline claims imply. As a result, the translational relevance of the frailty-stratified findings for sarcopenia case-finding remains unspecified.

A clinically-relevant portion of the longevity and cardiometabolic literature is supported only by mechanistic or surrogate evidence, leaving a gap between bench plausibility and bedside confirmation. Immunogenicity surrogates (Wen 2025; Wang 2026; Yingyounyong 2025; Bonduelle 2025) are used to bridge dose, frequency, and innate-immunity claims to clinical benefit, but Ioannidis 2005 (methodological reference) cautions that surrogate associations do not guarantee hard-outcome validity, and the present evidence base does not include the kind of large, blinded, hard-end-point randomized trial that would close that gap. The mechanistic-to-clinic bridge for outcomes such as dementia prevention, cardiovascular event reduction, and longevity in non-diabetic adults therefore rests on inference rather than direct within-corpus replication. [bundle:3] [bundle:8] [bundle:35] [bundle:40]

## Conclusion

Authoritative outcome-class tally: n=53; cardiometabolic=10; contextual other=26; dosing pharmacokinetics=3; frailty=1; immune=1; immune inflammation=1; longevity=8; mortality survival=1; safety comorbidity=2. The numerator for each category in this tally is the number of retained evidence rows with that classification; n is all retained evidence rows. These counts use the admitted manifest row set, not classified-candidate buckets.

Substantive conclusion for Influenza Vaccination Effects: the retained source set shows 53 sources across Contextual Adjacent Evidence admitted n=26, Cardiometabolic admitted n=10, Longevity admitted n=8, Dosing and Pharmacokinetics admitted n=3; receipt-level directions mixed=3, null=22, positive=13, unclear=15; leading source labels Chen 2025, Yingyounyong 2025, Wang 2025a. The paper does not establish standalone clinical actionability. [bundle:5] [bundle:8] [bundle:10]

The conclusion is limited to claims that survive source qualification, source-context checks, and final audit gates.

### Bounded conclusion

This synthesis supports a bounded interpretation across 53 included sources. Effect directions are null (n=22), unclear (n=19), positive (n=11), mixed (n=1), with 25 sources carrying source-traced p-values and 494 documented cross-source tensions. These counts define the ceiling for the paper's claim strength: the conclusion can identify where the corpus is coherent, but it cannot turn indirect, heterogeneous, or mixed evidence into a clinical recommendation.

The closing inference should therefore follow the evidence map rather than the topic label. Direct human sources carry the most weight when they measure clinically proximate outcomes in the population under review. Indirect clinical sources, reviews, mechanistic papers, and protocols remain useful, but they define context, plausibility, and uncertainty rather than proof of effect. Where directions conflict, the safer conclusion is that design, endpoint, eligibility, comparator, or follow-up differences may be controlling the signal. Where findings are null or mixed, those results remain part of the answer because they limit how far a positive or mechanistic claim can travel.

The practical takeaway is bounded and revisable. The paper can be interpreted as a source-traced map of what the current source set can support, not as a treatment guideline or a pooled efficacy claim. A stronger future conclusion would require aligned direct evidence, durable endpoints, and fewer unresolved cross-source tensions. Until then, the responsible conclusion is to preserve uncertainty, state the strongest supported signal narrowly, make the remaining research gaps visible, and keep downstream reuse tied to the same source-level limits.

## What This Synthesis Adds

This synthesis maps 53 included sources on Influenza Vaccination Effects across 8 outcome classes and a high-density pairwise disagreement map. It separates endpoint-specific evidence from broad clinical-translation claims so that favorable biomarker signals are not treated as proof of durable clinical benefit.

Across 53 curated reference papers, the evidence base for Influenza shows a context-dependent profile. Positive signals appear in: longevity, cardiometabolic. Null findings dominate: contextual other, cardiometabolic. The synthesis surfaces cross-study disagreements across outcome classes — see Cross-Domain Synthesis.

The strongest unresolved contrast is the null vs positive between Incalzi 2024 and Alotaibi 2026 on longevity (severity 4/5), which defines the boundary condition future studies must test rather than smooth over. [bundle:34] [bundle:52]

Prior reviews in the corpus (Alotaibi 2026, Liu 2025, Streeter 2022, Hosseini 2026) emphasize convergent signals on Influenza Vaccination Effects. This synthesis adds a design-level evidence-weighting layer and an explicit cross-study disagreement map, keeping boundary conditions visible instead of averaging them away in narrative summary. [bundle:34] [bundle:45] [bundle:49] [bundle:50]

### Boundary-Condition Matrix

| Evidence domain | Direct sources | Indirect / mechanism sources | Direction profile | Interpretation boundary |
|---|---:|---:|---|---|
| longevity | 0 | 8 | mixed, null, positive | conflict-resolution gap |
| cardiometabolic | 0 | 10 | null, positive, unclear | direct interventional hard-endpoint gap |
| frailty | 1 | 0 | positive | replication gap |
| dosing and pharmacokinetics | 0 | 3 | null, unclear | direct interventional hard-endpoint gap |
| immune and inflammation | 1 | 1 | unclear | replication gap |
| mortality and survival | 0 | 1 | positive | direct interventional hard-endpoint gap |
| safety and comorbidity | 0 | 2 | null, unclear | direct interventional hard-endpoint gap |
| contextual adjacent evidence | 10 | 16 | null, positive, unclear | replication gap |

### Evidence-Gap Priority

| Priority | Gap | Rationale |
|---|---|---|
| P1 | longevity: conflict-resolution gap | 0 direct and 8 indirect sources; direction profile: mixed, null, positive |
| P2 | cardiometabolic: direct interventional hard-endpoint gap | 0 direct and 10 indirect sources; direction profile: null, positive, unclear |
| P3 | frailty: replication gap | 1 direct and 0 indirect source; direction profile: positive |
| P4 | dosing and pharmacokinetics: direct interventional hard-endpoint gap | 0 direct and 3 indirect sources; direction profile: null, unclear |
| P5 | immune and inflammation: replication gap | 1 direct and 1 indirect sources; direction profile: unclear |

### Next-Study Design Recommendation

The next high-yield study for Influenza Vaccination Effects should target the **longevity** evidence gap, pre-register the primary endpoint, separate clinical from mechanistic endpoints, preserve safety and adherence capture, and include an analysis plan that can falsify the current boundary-condition claim rather than only confirming a favorable direction. Minimum useful design: at least 200 participants per arm, a priority population of adults or older adults with baseline risk in the target outcome domain, and follow-up lasting at least 24 weeks; shorter or smaller studies should be treated as hypothesis-generating.

## Evidence Snapshot

The manuscript foregrounds the load-bearing evidence; the full evidence tables remain in the supplement.

### Load-Bearing Included Studies

- Chen 2025; tier=A1; directness=direct; endpoint=contextual adjacent evidence; direction=unclear; representative statistic=P < 0.001. [bundle:5]
- Yingyounyong 2025; tier=A1; directness=direct; endpoint=immune; direction=unclear; representative statistic=P = 0.008. [bundle:8]
- Wang 2025a; tier=A1; directness=direct; endpoint=contextual adjacent evidence; direction=unclear; representative statistic=P < 0.001. [bundle:10]
- Wright 2025; tier=A1; directness=direct; endpoint=contextual adjacent evidence; direction=unclear; representative statistic=P = 0.042. [bundle:12]
- Espersen 2025b; tier=A1; directness=direct; endpoint=frailty; direction=positive; representative statistic=P < 0.001. [bundle:25]
- Wang 2024; tier=A1; directness=direct; endpoint=contextual adjacent evidence; direction=null. [bundle:28]
- Li 2025; tier=A1; directness=direct; endpoint=contextual adjacent evidence; direction=null. [bundle:33]
- Hansen 2025; tier=A1; directness=direct; endpoint=contextual adjacent evidence; direction=null. [bundle:38]
- Lin 2024; tier=A1; directness=direct; endpoint=contextual adjacent evidence; direction=null. [bundle:41]
- Katangwe-Chigamba 2025; tier=A1; directness=direct; endpoint=contextual adjacent evidence; direction=unclear; representative statistic=P = 0.045. [bundle:43]

### Source Classification Map

Each retained source is mapped to its public evidence role so the evidence landscape can be checked without opening the supplement.

- Chen 2025: outcome=contextual adjacent evidence; directness=direct; tier=A1; direction=unclear; claims=69. [bundle:5]
- Yingyounyong 2025: outcome=immune; directness=direct; tier=A1; direction=unclear; claims=59. [bundle:8]
- Wang 2025a: outcome=contextual adjacent evidence; directness=direct; tier=A1; direction=unclear; claims=56. [bundle:10]
- Wright 2025: outcome=contextual adjacent evidence; directness=direct; tier=A1; direction=unclear; claims=49. [bundle:12]
- Espersen 2025b: outcome=frailty; directness=direct; tier=A1; direction=positive; claims=31. [bundle:25]
- Wang 2024: outcome=contextual adjacent evidence; directness=direct; tier=A1; direction=null; claims=26. [bundle:28]
- Li 2025: outcome=contextual adjacent evidence; directness=direct; tier=A1; direction=null; claims=22. [bundle:33]
- Hansen 2025: outcome=contextual adjacent evidence; directness=direct; tier=A1; direction=null; claims=18. [bundle:38]
- Lin 2024: outcome=contextual adjacent evidence; directness=direct; tier=A1; direction=null; claims=14. [bundle:41]
- Katangwe-Chigamba 2025: outcome=contextual adjacent evidence; directness=direct; tier=A1; direction=unclear; claims=9. [bundle:43]
- Zhang 2024: outcome=contextual adjacent evidence; directness=direct; tier=A1; direction=null; claims=9. [bundle:44]
- Xie 2024: outcome=contextual adjacent evidence; directness=direct; tier=A1; direction=null; claims=5. [bundle:48]
- Alotaibi 2026: outcome=longevity; directness=review; tier=B1; direction=mixed; claims=21. [bundle:34]
- Liu 2025: outcome=longevity; directness=review; tier=B1; direction=positive; claims=7. [bundle:45]
- Hosseini 2026: outcome=longevity; directness=review; tier=B1; direction=positive; claims=4. [bundle:49]
- Streeter 2022: outcome=longevity; directness=review; tier=B1; direction=positive; claims=4. [bundle:50]
- Sun 2025: outcome=mortality survival; directness=indirect; tier=B2; direction=positive; claims=106. [bundle:1]
- Espersen 2025a: outcome=safety comorbidity; directness=indirect; tier=B2; direction=unclear; claims=97. [bundle:2]
- Wen 2025: outcome=dosing pharmacokinetics; directness=indirect; tier=B2; direction=unclear; claims=93. [bundle:3]
- Guo 2025: outcome=cardiometabolic; directness=indirect; tier=B2; direction=unclear; claims=76. [bundle:4]
- Fortunato 2025: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=unclear; claims=68. [bundle:6]
- Luo 2026: outcome=longevity; directness=indirect; tier=B2; direction=null; claims=61. [bundle:7]
- Yang 2024: outcome=cardiometabolic; directness=review; tier=B2; direction=null; claims=57. [bundle:9]
- Tadount 2025: outcome=cardiometabolic; directness=review; tier=B2; direction=null; claims=52. [bundle:11]
- Szilagyi 2025: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=unclear; claims=47. [bundle:13]
- Wang 2025b: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=unclear; claims=47. [bundle:14]
- Wang 2025c: outcome=cardiometabolic; directness=indirect; tier=B2; direction=positive; claims=46. [bundle:15]
- Appel 2025: outcome=longevity; directness=indirect; tier=B2; direction=positive; claims=44. [bundle:16]
- Jin 2026: outcome=cardiometabolic; directness=review; tier=B2; direction=unclear; claims=43. [bundle:17]
- Alshagrawi 2025: outcome=contextual adjacent evidence; directness=review; tier=B2; direction=unclear; claims=34. [bundle:19]
- Rocinova 2026: outcome=contextual adjacent evidence; directness=review; tier=B2; direction=positive; claims=33. [bundle:20]
- Papagiannis 2024: outcome=contextual adjacent evidence; directness=review; tier=B2; direction=unclear; claims=32. [bundle:21]
- Jiang 2025: outcome=safety comorbidity; directness=review; tier=B2; direction=null; claims=31. [bundle:24]
- Krishnan 2026: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=31. [bundle:23]
- Wei 2026: outcome=cardiometabolic; directness=review; tier=B2; direction=unclear; claims=31. [bundle:22]
- Chaves 2026: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=28. [bundle:26]
- Chiu 2025: outcome=cardiometabolic; directness=indirect; tier=B2; direction=positive; claims=26. [bundle:27]
- Hu 2024: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=unclear; claims=26. [bundle:29]
- Alshahrani 2025: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=positive; claims=25. [bundle:30]
- Andrew 2004: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=unclear; claims=24. [bundle:53]

### Classification Criteria

- **Outcome class** is assigned from the source's bound endpoint, population, and claim text; adjacent/background sources are separated from clinical outcome slices.
- **Directness** is coded as direct only when a source tests the topic against a clinically proximate outcome in the relevant population; a qualifying direct source would be a human interventional or hard-endpoint study of the topic itself. Indirect human, review-level, and mechanistic sources are weighted separately.
- **Directional signal** is counted within the assigned outcome class only. A `no extracted directional signal` cell means the retained sources in that outcome slice did not yield a coded positive, negative, or mixed direction for that slice; it is not a claim that the source reports no associations anywhere else.
- **Evidence tier** follows the deterministic tier/directness taxonomy used in the source builder; the prose writer cannot move a source between classes after sources are frozen.

### Load-Bearing Tensions

- Severity 4 null vs positive: Incalzi 2024 vs Alotaibi 2026; Alotaibi 2026 (positive on mortality) vs Incalzi 2024 (null on mortality) — partial conflict [bundle:34] [bundle:52]
- Severity 4 null vs positive: Luo 2026 vs Alotaibi 2026; Alotaibi 2026 (positive on mortality) vs Luo 2026 (null on mortality) — partial conflict [bundle:7] [bundle:34]
- Severity 3 indirectness gap: Wang 2024 vs Hu 2024; Wang 2024 (direct, A1) vs Hu 2024 (indirect) on contextual other — direct vs indirect must be kept separate [bundle:28] [bundle:29]
- Severity 3 indirectness gap: Wang 2024 vs Papagiannis 2024; Wang 2024 (direct, A1) vs Papagiannis 2024 (review) on contextual other — direct vs indirect must be kept separate [bundle:21] [bundle:28]
- Severity 3 indirectness gap: Wang 2024 vs Alshagrawi 2025; Wang 2024 (direct, A1) vs Alshagrawi 2025 (review) on contextual other — direct vs indirect must be kept separate [bundle:19] [bundle:28]
- Severity 3 indirectness gap: Wang 2024 vs Mora 2025; Wang 2024 (direct, A1) vs Mora 2025 (indirect) on contextual other — direct vs indirect must be kept separate [bundle:28] [bundle:37]
- Severity 3 indirectness gap: Wang 2024 vs Szilagyi 2025; Wang 2024 (direct, A1) vs Szilagyi 2025 (indirect) on contextual other — direct vs indirect must be kept separate [bundle:13] [bundle:28]
- Severity 3 indirectness gap: Wang 2024 vs Wang 2025b; Wang 2024 (direct, A1) vs Wang 2025b (indirect) on contextual other — direct vs indirect must be kept separate [bundle:14] [bundle:28]

## Quantitative Evidence Index — influenza vaccination effects

_Quantitative Evidence Index: top 27 high-confidence numeric claims from the corpus. Every row traces to a corpus-bound claim and a registered citation._

**Numeric verification note:** P-values are rendered from extracted source statistics; rounded zero values are reported at their implied decimal floor rather than as impossible zero probabilities.

| Study | Endpoint | Arm | Value | Type | Statistic |
|---|---|---|---|---|---|
| Sun 2025 | mortality | influenza vaccination | HR = 0.61 | hazard ratio | — | [bundle:1]
| Liu 2025 | cardiovascular events | control | RR = 0.55 | risk ratio | — | [bundle:45]
| Liu 2025 | mortality | control | RR = 0.58 | risk ratio | — | [bundle:45]
| Hosseini 2026 | mortality | influenza vaccination | HR = 0.72 | hazard ratio | — | [bundle:49]
| Appel 2025 | mortality | — | HR: 0.85 | hazard ratio | — | [bundle:16]
| Hosseini 2026 | cardiovascular events | — | HR = 0.81 | hazard ratio | — | [bundle:49]
| Guo 2025 | cardiovascular events | influenza vaccination | — | 95%CI | (0.83–0.89) | [bundle:4]
| Alotaibi 2026 | mortality | influenza vaccination | — | 95%CI | (0.57–0.90) | [bundle:34]
| Alotaibi 2026 | cardiovascular events | influenza vaccination | — | 95%CI | (0.26–0.74) | [bundle:34]
| Jin 2026 | cardiovascular events | influenza vaccination | — | 95%CI | (0.52–0.87) | [bundle:17]
| Papagiannis 2024 | mortality | — | P = 0.015 | p-value | — | [bundle:21]
| Bonduelle 2025 | vaccine response | — | P < 0.05 | p-value | — | [bundle:40]
| Wang 2025c | body mass index | — | P > 0.05 | p-value | — | [bundle:15]
| Espersen 2025b | frailty | — | P < 0.001 | p-value | — | [bundle:25]
| Yingyounyong 2025 | vaccine response | influenza vaccination | 25% | % | — | [bundle:8]
| Dehesh 2025 | adverse events | influenza vaccination | 27% | % | — | [bundle:39]
| Wright 2025 | mortality | control | 55% | % | — | [bundle:12]
| Leung 2025 | mortality | influenza vaccination | 39% | % | — | [bundle:36]
| Guo 2025 | body mass index | control | 30% | % | — | [bundle:4]
| Yang 2025 | mortality | influenza vaccination | 10% | % | — | [bundle:42]
| Tadount 2025 | mortality | influenza vaccination | 67% | % | — | [bundle:11]
| Tadount 2025 | cardiovascular events | influenza vaccination | 33% | % | — | [bundle:11]
| Fortunato 2025 | inflammation | influenza vaccination | 34.5% | % | — | [bundle:6]
| Andrew 2004 | mortality | influenza vaccination | 55.2% | % | — | [bundle:53]
| Streeter 2022 | mortality | influenza vaccination | 95% | % | — | [bundle:50]
| Papagiannis 2024 | cardiovascular events | — | 2.9% | % | — | [bundle:21]
| Pedersen 2024 | blood glucose | — | 11.1 mmol/L | mmol/L | — | [bundle:18]

## References

- **Sun 2025.** _Effect of Current-Season-Only Versus Continuous Two-Season Influenza Vaccination on Mortality in Older Adults: A Propensity-Score-Matched Retrospective Cohort Study._ Vaccines, 2025. DOI: 10.3390/vaccines13020164 PMID: 40006711.
- **Espersen 2025a.** _Electronic nudges to increase influenza vaccination uptake in younger and middle-aged individuals with atrial fibrillation: a prespecified analysis of the NUDGE-FLU-CHRONIC trial._ European Heart Journal Open, 2025. DOI: 10.1093/ehjopen/oeaf160 PMID: 41536962.
- **Wen 2025.** _Immunogenicity and safety of 1 versus 2 doses of quadrivalent-inactivated influenza vaccine in children aged 3–8 years with or without previous influenza vaccination histories._ Human Vaccines & Immunotherapeutics, 2025. DOI: 10.1080/21645515.2025.2468074 PMID: 39993940.
- **Guo 2025.** _Estimating cardiovascular effects of influenza vaccination in older adults: a target trial emulation using proximal causal inference._ eClinicalMedicine, 2025. DOI: 10.1016/j.eclinm.2025.103449 PMID: 40896461.
- **Chen 2025.** _Impact of multifaceted health education on influenza vaccination health literacy in primary school students: a cluster randomized controlled trial._ BMC Medicine, 2025. DOI: 10.1186/s12916-025-04156-1 PMID: 40468328.
- **Fortunato 2025.** _Association of socio-economic and clinical factors with influenza vaccination uptake in high-risk individuals: an Italian retrospective cohort study, 2019–2023._ International Journal of Health Geographics, 2025. DOI: 10.1186/s12942-025-00446-2 PMID: 41455971.
- **Luo 2026.** _Impacts of delayed influenza vaccination on clinical outcomes in ICU-admitted patients with influenza: A retrospective cohort study._ Virus Research, 2026. DOI: 10.1016/j.virusres.2026.199700 PMID: 41643751.
- **Yingyounyong 2025.** _A study of booster dose influenza vaccination responses compared to standard dose in lupus patients: an open-labeled, randomized controlled study._ Clinical and Experimental Medicine, 2025. DOI: 10.1007/s10238-025-01639-6 PMID: 40205278.
- **Yang 2024.** _Influenza Vaccination Coverage and Influencing Factors in Type 2 Diabetes in Mainland China: A Systematic Review and Meta-Analysis._ Vaccines, 2024. DOI: 10.3390/vaccines12111259 PMID: 39591162.
- **Wang 2025a.** _A cluster randomised trial of digital messaging nudges to improve influenza vaccination uptake in China._ NPJ Digital Medicine, 2025. DOI: 10.1038/s41746-025-02137-5 PMID: 41310039.
- **Tadount 2025.** _Does influenza vaccination contribute to the prevention of cardiovascular events? An umbrella review._ Canada Communicable Disease Report, 2025. DOI: 10.14745/ccdr.v51i09a02 PMID: 41393795.
- **Wright 2025.** _Effectiveness of a theory-informed intervention to increase care home staff influenza vaccination rates: a cluster randomised controlled trial._ Journal of Public Health (Oxford, England), 2025. DOI: 10.1093/pubmed/fdaf023 PMID: 40158203.
- **Szilagyi 2025.** _Video and Infographic Messages From Primary Care Physicians and Influenza Vaccination Rates._ JAMA Network Open, 2025. DOI: 10.1001/jamanetworkopen.2025.26514 PMID: 40802184.
- **Wang 2025b.** _Effectiveness, Usability, and Acceptability of ChatGPT With Retrieval-Augmented Generation (SIV-ChatGPT) in Increasing Seasonal Influenza Vaccination Uptake Among Older Adults: Quasi-Experimental Study._ Journal of Medical Internet Research, 2025. DOI: 10.2196/76849 PMID: 40921067.
- **Wang 2025c.** _Influenza Vaccination and Short‐Term Risk of Stroke Among Elderly Patients With Chronic Comorbidities in a Population‐Based Cohort Study._ The Journal of Clinical Hypertension, 2025. DOI: 10.1111/jch.70044 PMID: 40751465.
- **Appel 2025.** _The Effect of Influenza Vaccination on Hospitalization and Mortality Among People With Dementia._ Journal of the American Geriatrics Society, 2025. DOI: 10.1111/jgs.19392 PMID: 40123175.
- **Jin 2026.** _Influenza vaccination and cardiovascular and respiratory outcomes in high-risk populations: an umbrella review of systematic reviews and meta-analyzes._ Frontiers in Immunology, 2026. DOI: 10.3389/fimmu.2026.1798398 PMID: 42273673.
- **Pedersen 2024.** _INfluenza VaccInation To mitigate typE 1 Diabetes (INVITED): a study protocol for a randomised, double-blind, placebo-controlled clinical trial in children and adolescents with recent-onset type 1 diabetes._ BMJ Open, 2024. DOI: 10.1136/bmjopen-2024-084808 PMID: 38950997.
- **Alshagrawi 2025.** _Impact of COVID-19 pandemic on influenza vaccination rates among healthcare workers and the general population in Saudi Arabia: A meta-analysis._ Human Vaccines & Immunotherapeutics, 2025. DOI: 10.1080/21645515.2025.2477954 PMID: 40068961.
- **Rocinova 2026.** _Factors influencing the relationship between influenza vaccination and the risk of developing dementia: A systematic review._ Journal of Alzheimer's Disease, 2026. DOI: 10.1177/13872877261420240 PMID: 41736221.
- **Papagiannis 2024.** _Pneumococcal and Influenza Vaccination Coverage in Patients with Heart Failure: A Systematic Review._ Journal of Clinical Medicine, 2024. DOI: 10.3390/jcm13113029 PMID: 38892740.
- **Jiang 2025.** _Barriers to influenza vaccination in older adults with chronic diseases: Insights from a COM-B model–based meta-analysis._ Human Vaccines & Immunotherapeutics, 2025. DOI: 10.1080/21645515.2025.2574732 PMID: 41128133.
- **Espersen 2025b.** _Relative Effectiveness of High-Dose Versus Standard-Dose Influenza Vaccination Against Hospitalizations and Deaths According to Frailty Score: A Post Hoc Analysis of the DANFLU-1 Randomized Trial._ The Journal of Infectious Diseases, 2025. DOI: 10.1093/infdis/jiaf420 PMID: 40796377.
- **Wei 2026.** _The benefits of influenza vaccination in patients with cardiovascular disease: a systematic review and meta-analysis._ Frontiers in Pharmacology, 2026. DOI: 10.3389/fphar.2025.1701127 PMID: 41640676.
- **Krishnan 2026.** _Burden of Influenza and Cost‐Effectiveness Analysis of Introduction of an Influenza Vaccination Programme Among Older Adults in India._ Influenza and Other Respiratory Viruses, 2026. DOI: 10.1111/irv.70264 PMID: 42062199.
- **Chaves 2026.** _Monitoring influenza vaccination coverage among older adults: a rural cohort study, Rio Grande, 2017-2022._ Epidemiologia e Serviços de Saúde : Revista do Sistema Unico de Saúde do Brasil, 2026. DOI: 10.1590/S2237-96222026v35e20250561.en PMID: 41880426.
- **Wang 2024.** _Nudging towards COVID-19 and influenza vaccination uptake in medically at-risk children: EPIC study protocol of randomised controlled trials in Australian paediatric outpatient clinics._ BMJ Open, 2024. DOI: 10.1136/bmjopen-2023-076194 PMID: 38367966.
- **Hu 2024.** _Effectiveness of Multifaceted Strategies to Increase Influenza Vaccination Uptake._ JAMA Network Open, 2024. DOI: 10.1001/jamanetworkopen.2024.3098 PMID: 38526493.
- **Chiu 2025.** _Big data analysis of influenza vaccination and liver cancer risk in hypertensive patients: insights from a nationwide population-based cohort study._ BMC Gastroenterology, 2025. DOI: 10.1186/s12876-025-03665-w PMID: 39994561.
- **Alshahrani 2025.** _Influenza Vaccination and Morbidity Among Sudanese Hajj Pilgrims During the 2025 Hajj._ Vaccines, 2025. DOI: 10.3390/vaccines13111134 PMID: 41295507.
- **Bukhbinder 2026.** _Risk of Alzheimer Dementia After High-Dose vs Standard-Dose Influenza Vaccination._ Neurology, 2026. DOI: 10.1212/WNL.0000000000214782 PMID: 41921123.
- **McConeghy 2025.** _Recombinant vs Egg-Based Quadrivalent Influenza Vaccination for Nursing Home Residents._ JAMA Network Open, 2025. DOI: 10.1001/jamanetworkopen.2024.52677 PMID: 39745702.
- **Andrew 2004.** _Rates of influenza vaccination in older adults and factors associated with vaccine use: A secondary analysis of the Canadian Study of Health and Aging._ BMC Public Health, 2004. DOI: 10.1186/1471-2458-4-36 PMID: 15306030.
- **Li 2025.** _Effectiveness of pay it forward intervention compared to free and user-paid vaccinations on seasonal influenza vaccination among older adults across seven cities in China: study protocol of a three-arm cluster randomized controlled trial._ BMC Public Health, 2025. DOI: 10.1186/s12889-025-23301-2 PMID: 40610910.
- **Alotaibi 2026.** _Impact of Influenza Vaccination on Mortality and Major Cardiovascular Events in Adults with Cardiovascular Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials._ Vaccines, 2026. DOI: 10.3390/vaccines14040309 PMID: 42042785.
- **Wang 2026.** _Repeated Annual Influenza Vaccination in Older Adults Induces Comparable Seroprotection Despite Reduced Antibody Fold Rise: A 6-Month Prospective Cohort Study in China._ Vaccines, 2026. DOI: 10.3390/vaccines14040338 PMID: 42042813.
- **Leung 2025.** _The effect of SARS-CoV-2 and influenza vaccination on endemic coronavirus-related mortality: A retrospective cohort study in Brazil._ Human Vaccines & Immunotherapeutics, 2025. DOI: 10.1080/21645515.2025.2516314 PMID: 40497727.
- **Mora 2025.** _Determinants of influenza vaccination uptake among older adults in Catalonia using a longitudinal population study: the role of public health campaigns._ BMJ Public Health, 2025. DOI: 10.1136/bmjph-2025-002698 PMID: 40791265.
- **Hansen 2025.** _Effectiveness of Text Messaging Nudging to Increase Coverage of Influenza Vaccination Among Older Adults in Norway (InfluSMS Study): Protocol for a Randomized Controlled Trial._ JMIR Research Protocols, 2025. DOI: 10.2196/63938 PMID: 39998878.
- **Dehesh 2025.** _Influenza Vaccination and Cardiovascular Outcomes in Patients with Coronary Artery Diseases: A Placebo-Controlled Randomized Study, IVCAD._ Vaccines, 2025. DOI: 10.3390/vaccines13050472 PMID: 40432084.
- **Lin 2024.** _Promoting Influenza Vaccination Uptake Among Chinese Older Adults Based on Information–Motivation–Behavioral Skills Model and Conditional Economic Incentive: Protocol for Randomized Controlled Trial._ Healthcare, 2024. DOI: 10.3390/healthcare12232361 PMID: 39684983.
- **Bonduelle 2025.** _Boosting effect of high-dose influenza vaccination on innate immunity among elderly._ JCI Insight, 2025. DOI: 10.1172/jci.insight.184128 PMID: 40036077.
- **Yang 2025.** _Influenza vaccination and ischemic stroke risk reduction in elderly stroke survivors: a retrospective cohort study with negative control validation._ BMC Geriatrics, 2025. DOI: 10.1186/s12877-025-06695-x PMID: 41315989.
- **Zhang 2024.** _Influenza vaccination in patients with acute heart failure (PANDA II): study protocol for a hospital-based, parallel-group, cluster randomized controlled trial in China._ Trials, 2024. DOI: 10.1186/s13063-024-08452-8 PMID: 39587669.
- **Katangwe-Chigamba 2025.** _Process evaluation of the flucare cluster randomised controlled trial: assessing the implementation of a behaviour change intervention to increase influenza vaccination uptake among care home staff in England._ BMC Health Services Research, 2025. DOI: 10.1186/s12913-025-13298-0 PMID: 40835927.
- **Liu 2025.** _Association between influenza vaccination and prognosis in patients with ischemic heart disease: A systematic review and meta-analysis of randomized controlled trials._ Travel Med Infect Dis, 2025. DOI: 10.1016/j.tmaid.2024.102793 PMID: 39710016.
- **Pagkozidis 2026.** _Strategies to Enhance Seasonal Influenza Vaccination Uptake: Qualitative Insights from Primary Care Physicians in Greece._ Vaccines, 2026. DOI: 10.3390/vaccines14050458 PMID: 42188828.
- **Xie 2024.** _Impact of health education on promoting influenza vaccination health literacy in primary school students: a cluster randomised controlled trial protocol._ BMJ Open, 2024. DOI: 10.1136/bmjopen-2023-080115 PMID: 38609315.
- **Abbasian 2025.** _Investigating the relationship between influenza vaccination and COVID-19 infection: a cohort study in Tehran._ BMC Infectious Diseases, 2025. DOI: 10.1186/s12879-025-12392-2 PMID: 41449332.
- **Streeter 2022.** _Influenza vaccination reduced myocardial infarctions in United Kingdom older adults: a prior event rate ratio study._ J Clin Epidemiol, 2022. DOI: 10.1016/j.jclinepi.2022.06.018 PMID: 35817230.
- **Hosseini 2026.** _Mortality and Morbidity Benefit After Influenza Vaccination in High Cardiovascular Risk Population: A Systematic Review and Meta-analysis._ Am J Cardiol, 2026. DOI: 10.1016/j.amjcard.2026.03.040 PMID: 41951138.
- **Blandi 2026.** _From breath to brain: influenza vaccination as a pragmatic strategy for dementia prevention._ Aging Clinical and Experimental Research, 2026. DOI: 10.1007/s40520-026-03323-5 PMID: 41543642.
- **Incalzi 2024.** _Influenza vaccination for elderly, vulnerable and high-risk subjects: a narrative review and expert opinion._ Internal and Emergency Medicine, 2024. DOI: 10.1007/s11739-023-03456-9 PMID: 37891453.

{
  "article_type": "evidence_map",
  "domain_slug": "longevity",
  "researka_object_type": "submission",
  "researka_submission_id": "14d6e135-7093-4bea-9f71-088d194e3552",
  "title": "Research Synthesis: Influenza Vaccination Effects \u2014 full paper"
}